

Biomimetic scaffolds based on chitosan in bone regeneration. A review.

Anna Kołakowska¹, Agnieszka Gadomska-Gajadur², and Paweł Ruśkowski³

¹Politechnika Warszawska

²Warsaw University of Technology

³NA

September 25, 2021

Abstract

The article focuses on a polysaccharide of natural origin – chitosan and its application in tissue engineering. The preparation process and physicochemical properties of the saccharide are described. The degradation of chitosan and the properties influencing the process both outside and in living organism were examined. Four applications in bone tissue engineering can be distinguished: preparation of cell scaffolds exclusively from chitosan, from a chitosan composite or from a chitosan polyelectrolyte complex. The fourth way is to modify the surface of scaffolds made of other materials by covering them with a layer of chitosan. At the end of the article, the processes taking place after placing the implant inside the body are described, how the structure of chitosan affects the behaviour of bone cells in the adhesion process and life processes.

Biomimetic scaffolds based on chitosan in bone regeneration. A review.

Anna Kołakowska¹, Agnieszka Gadomska-Gajadur^{1*}, Paweł Ruśkowski¹

¹ Faculty of Chemistry, Warsaw University of Technology, Noakowskiego 3, 00-664 Warsaw, Poland.

KEYWORDS: chitosan, scaffolds, biocompatibility, bone regeneration

ABSTRACT:

The article focuses on a polysaccharide of natural origin – chitosan and its application in tissue engineering. The preparation process and physicochemical properties of the saccharide are described. The degradation of chitosan and the properties influencing the process both outside and in living organism were examined. Four applications in bone tissue engineering can be distinguished: preparation of cell scaffolds exclusively from chitosan, from a chitosan composite or from a chitosan polyelectrolyte complex. The fourth way is to modify the surface of scaffolds made of other materials by covering them with a layer of chitosan. At the end of the article, the processes taking place after placing the implant inside the body are described, how the structure of chitosan affects the behaviour of bone cells in the adhesion process and life processes.

INTRODUCTION

Bone lesions are common injuries. In some cases, with a sufficiently small size of the defect, the bone is able to regenerate itself.¹ In optimal conditions, healing can take place without scarring, i.e. in such a way that the regenerated tissue is indistinguishable from the state before the damage.² There are also injuries that cannot regenerate spontaneously, despite surgical intervention and stabilisation, they require special treatment. Such injuries are called critical defects. It is assumed that the size of such lesions is approx. 1–2 cm and more than 50% of the bone volume is affected.³ Regeneration of such defects is complicated, difficult to control, until now it has involved autologous bone transplant surgery.⁴ This technique is relatively good

due to its histocompatibility and non-immunogenicity. It also has its disadvantages, such as the formation of damage at the site of extraction of the implant tissue, risk of secondary damage, scarring, distortion, and others.^{5,6} Tissue engineering is also involved in the treatment of such critical lesions and is an alternative to conventional transplants. It is possible to use scaffolds made from biomaterials, which will provide a place for attachment for new bone cells and form the basis for the reconstruction process.^{7,8}

Biomaterials are the basic materials used in tissue engineering. It is a group of compounds that can come into direct contact with tissues and are well tolerated by the body. Biomaterials must be biocompatible, effective and sterilisable.^{9,10} There are three generations of biomaterials, chronologically these are inert materials, bioactive materials and biomimetic materials. The inert materials replace the damaged organ or its fragment without interacting with the body. Bioactive materials combine with tissue through biochemical reactions and can replace the damaged element. Biomimetic materials are designed to stimulate the growth and proliferation of cells on the surface of the material. They are characterised by both bioactivity and biore-sorbability. This group includes biodegradable scaffolds, which are a place for cell attachment, later tissue development and decay over time.^{11,12} The aim of the literature review was to study the popular polysaccharide of natural origin – chitosan, its properties, behaviour in contact with body cells and applications in bone tissue engineering.

Chitosan

Chitosan (CS) is a derivative of the natural polysaccharide – chitin (Figure 1). CS is obtained by partial deacetylation of chitin in which at least half of the acetyl groups are removed. Chitosan is a linear cationic polymer, a copolymer composed of *N*- acetyl-*D*- glucosamine and *D*- glucosamine units linked by β -1,4-glycosidic bonds.

Preparation and chemical structure

The source of chitosan is chitin – the second most common polysaccharide in nature.¹³ CI is one of the main building blocks of arthropod skeletons, some molluscs and fungal cell walls.^{14,15} Industrial chitin is most often obtained from food industry waste, crustaceans or sea molluscs (shrimps, lobsters, crabs, squid, mussels),^{16–19} it may also be of fungal origin.²⁰

Obtaining chitin

Due to its low solubility in popular solvents, chitin is obtained as a result of a multi-stage extraction process (chemical purification). The steps in this process are demineralisation , deproteinisation, and discolouration may also be performed (Figure 2).

The dried shells of crustaceans are demineralised by acid to remove minerals, especially calcium (hence in some sources this stage is called decalcination). The most common is an aqueous HCl solution (up to 10% concentration), but also HNO₃, H₂SO₄, HCOOH or a more environmentally friendly acetic acid solution are commonly used.^{21,22} The insoluble residue is centrifuged and then repeatedly washed with water until the pH is neutral. In the deproteinisation step, the residues are treated with alkalines in order to remove proteins from them. Most often, solutions of monohydroxy bases are used, e.g. NaOH, KOH, but also salt solutions such as Na₂CO₃, NaHCO₃, K₂CO₃, NaHSO₃.²³ The fractions are separated again, washed with water until neutral pH and dried. Thus obtained chitin has a pinkish colour.¹³ Chitin discolouration takes place under the influence of an oxidant, e.g. KMnO₄, H₂O₂, then the precipitate is washed with a solution of oxalic acid. In this way, colourless, pure chitin is obtained.^{13,22} It is also possible to purify chitin biologically with the use of enzymes – proteases^{24–26} or microbes in the fermentation process.²⁷

Preparation of chitosan

The purified chitin is subjected to a deacetylation process (Figure 2). To this end, the CI is treated with a concentrated base, most often NaOH,²¹ and then washed with water and dried. The chitosan thus obtained is in the form of a white powder.¹³

In the deacetylation process random acetyl groups are removed in favour of the amino group, chitosan is a copolymer of *N*-acetyl-*D*-glucosamine and *D*-glucosamine units. The presence of the latter groups depends on the degree of deacetylation (DD) that is used to characterise the CS. The more deacetylated the CS is, the fewer *N*-acetyl-*D*-glucosamine groups. The value of the DD of chitosan is in the range of 50–95%.^{17,28}

Physicochemical properties

In its structure, chitosan contains functional groups: hydroxyl, amine and acetyl. They have a significant impact on the chemical properties of the polymer and the nature of interactions. The presence of hydrophobic acetyl groups and hydrophilic amine and hydroxyl groups ensures the amphiphilic nature of the polymer.¹³ The amine groups that are responsible for the cationic nature of the polymer result in a high surface tension of aqueous solutions of this polysaccharide.²⁹

CS is insoluble in water, in popular organic solvents (including methanol, ethanol, isopropanol, toluene), however, it dissolves in dilute aqueous acid solutions, e.g. in hydrochloric acid, acetic acid, formic acid, citric acid.^{30–32} This property is due to the presence of free amino groups that can protonate at a pH below 6.³³ The amine groups become positively charged, breaking the hydrogen bonds and allowing the polymer to dissolve. Above this pH value, the -NH_3^+ groups deprotonate, lose their charge, and the polymer solubility decreases.^{16,34} The results of the solubility tests are presented in Table 1.³⁰

The solubility of chitosan also depends on the degree of deacetylation (DD) and the molecular weight of the polysaccharide. The more amino groups there are, i.e. the higher the deacetylation degree, the better the chitosan solubility.²³ The higher the molecular weight of the polymer, the more internal hydrogen bonds there are and the more difficult it is to dissolve.¹⁷ CS forms water-soluble salts, including formates, acetates, hydrochlorides, citrates.³⁵ To characterise chitosan, its viscosity is often used, which depends on various parameters such as concentration of chitosan in the solution, temperature, degree of deacetylation.³⁶

The cationic nature of chitosan distinguishes it from other natural polysaccharides. Due to its positive charge, chitosan has the ability to form complexes with negatively charged compounds, e.g. polylactide³⁷, poly(glutamic acid)³⁸, DNA^{39,40}, collagen⁴¹, alginates^{42–44}, hyaluronic acid^{45–47}, pectin^{48,49} and many others.

The structure of chitosan, which is based on *D*-glucosamine and *N*-acetyl-*D*-glucosamine units, is similar to the structure of naturally occurring glycosaminoglycans (GAG). GAG can build the extracellular matrix and perform various functions in organisms, e.g. they affect adhesion, growth factors and cell receptors, water retention (influencing the resistance of cells to compression). It can be expected that, thanks to its GAG-like structure, chitosan can also interact with animal cells.^{7,34}

Chitosan is readily used in tissue engineering because it is characterised by features desired in biomaterials: biocompatibility, non-toxicity, the ability to biodegrade into non-toxic compounds and bioactivity.^{50–52} It also demonstrates osteocompatibility (the presence of chitosan does not adversely affect bone regeneration) and osteoconduction (the ability to connect with bone tissue and stimulate its growth).¹³ CS also has mucoadhesive properties, i.e. it promotes the adhesion of animal mucus cells to the biomaterial. This property is due to the difference in charges between positive chitosan and negative mucus, between which electrostatic interactions are generated.^{53,54} CS is also credited with the ability to inhibit the growth of neoplastic cells^{55,56} and promote wound healing.^{57–60} Chitosan also has antibacterial and antifungal properties (against Gram-positive⁶¹ and Gram-negative bacteria⁶²). These properties are probably due to the interaction between the positively charged polymer and negatively charged lipopolysaccharides or proteins in microbial membranes.⁵⁹ Interactions with the surface of the bacterial cell reduce the permeability. The antibacterial properties of chitosan may also result from the interaction with the DNA of the bacterial cell, which results in inhibition of RNA synthesis.^{50,59,63}

Chitosan degradation

Chitosan is a natural polymer which decomposes under the influence of both chemical and physical factors and enzymes. Chemical factors include depolymerisation under the influence of strong acids, e.g. HCl, HNO_2 , H_3PO_4 , CH_3COOH ,^{64–66} strong oxidants⁶⁷ or free radicals.⁶⁸ The products of such reactions are

chitosan oligosaccharides with various, low molecular weights.⁶⁹ Chemical degradation is a fast process, but expensive, poorly controlled (random cutting of the polymer chain⁷⁰) and highly polluting towards the environment due to the chemical compounds used.^{55,65,71}

Physical methods of CS depolymerisation include, among others, γ radiation, ultrasound. Contrary to chemical depolymerisation, mechanical cuts occur more frequently inside the polymer,⁷² and the obtained oligosaccharides are characterised by a narrower size distribution.⁶⁹ Gamma radiation can be used to sterilise chitosan products. It was examined that under the influence of gamma radiation the CS structure changes, there is a decrease in molecular weight already at 15 kGy, which increases with radiation dosage.⁷³ Such changes may affect the properties of the polymer and, consequently, the chitosan-containing medical device. The use of ultrasound is a popular solution due to its low environmental impact. Degradation of chitosan by ultrasound is based on mechanical phenomena and depends on wave intensity, temperature, polymer concentration, ionic forces.⁷⁴ There are also studies on CS depolymerisation using the cavitation process.^{69,75,76}

The use of enzymes for the depolymerisation of CS is associated with carrying out the reaction in mild conditions and fairly good control of the process. It is also an environmentally friendly method.^{64,65} The enzyme specific chitosanase can be used in the hydrolysis of β -1,4-glycosidic bonds, as well as non-specific chitinases⁷⁷, lysozym⁷⁸ or cellulases.⁷¹ The reduction of the CS molecular weight under the influence of the protease enzyme changed the structure of the oligomer, but did not affect the deacetylation degree.⁷⁹ Proteases can also be used for the production of monomers (*N*-acetyl-*D*-glucosamine units).⁸⁰ The use of lipase, the enzyme present in the human body, in CS depolymerisation leads to products with different molecular sizes in the 30 – 50 kDa range, without major structural changes to the polymer.⁸¹

Metabolism in living organisms

A biodegradable scaffold used in bone regeneration should degrade in the body into known, non-toxic products that can be excreted from the body or incorporated into the body's natural metabolic cycles. The time of scaffold degradation in the body depends on the place of implanting and the patient (their age, chronic diseases), but on average in bone regeneration it should take from 3 to 9 months.⁸² Hydrolysis of glycosidic bonds in chitosan leads to the production of non-toxic glucosamine oligosaccharides, which can be rapidly cleared from the body in urine.^{83,84} Chitosan implants do not elicit a long-lasting inflammatory or immune response.⁵² The inflammation observed after the introduction of chitosan scaffolds depends on the degree of deacetylation of the polysaccharide. Chitosan with a lower DD induced a stronger leukocyte response.⁸⁵ The rate of degradation of chitosan implemented in the form of microspheres, hydrogels or 3D scaffolds varies. The onset of degradation of chitosan in the form of microspheres was observed 4 weeks after introduction into the body of rats, and after 12 weeks the microspheres disintegrated into small fragments.⁸⁶ For chitosan hydrogel, strong degradation was observed after 4 weeks.⁸⁷ In turn, the 3D porous scaffold made of chitosan after 30 days *in vivo* was completely biodegraded.⁸⁸ Hydrolysis of bonds in chitosan takes place in the human body under the influence of a non-specific enzyme lysozyme.⁸⁹ It has been noted that due to the cationic nature of chitosan, it can interact with blood cells. In the presence of chitosan, blood tends to coagulate and form clots on the surface of chitosan.⁹⁰ After oral administration of a polysaccharide in the organisms of rabbits, a specific response was observed, i.e. an increase in lysozyme secretion by the organism, which may prevent thrombosis.⁹¹ *In vivo* degradation studies of chitosan-poly-L-lactide composites in rats showed that the polysaccharide did not cause an unexpected, negative response, no blood clots were detected after 1 week.⁹²

Cell scaffolding

Tissue engineering is looking for solutions that could replace the need for autographic or allographic transplants. One of the proposed solutions is the use of scaffolds that mimic the basic roles of tissues and enable their regeneration.^{93,94}

Such scaffolding is usually a three-dimensional, porous structure made of biomaterial. The main task of scaffolding is to support the regenerating tissue by providing a rack on the surface of which cells can settle.⁸

Scaffolds should imitate the tissue for which they are used to regenerate, its structure and properties.⁹⁵ The implant must not cause a negative immune response, it should be metabolised by the body, easy to shape and sterilise, and it should be durable so that it can be stored in *ex vivo* conditions.⁹⁶

Scaffolds made of chitosan alone

Due to the properties of chitosan, such as non-toxicity, biocompatibility, affinity to animal mucus and biodegradability, it is a polymer very readily used in tissue engineering.⁴ It supports cell adhesion and proliferation, and thus tissue regeneration. It allows you to easily model the scaffolding to a specific shape and create porous structures with open pores. These features make chitosan a potential candidate for scaffolding material.⁹⁷

The temperatures used during the production of 3D scaffolding significantly affect, among others, the pore size or mechanical properties related to the compressive modulus.⁹⁸ Chitosan with a higher degree of deacetylation was characterised by higher mechanical resistance, slower degradation time and lower absorbability of the scaffold.⁹⁹ High DD (DD 88% and 95% tested) supports cell proliferation on the surface of the chitosan scaffold.⁹⁹ The porosity of the scaffold has a significant influence on its mechanical properties. The more porous the structure, the worse the mechanical properties. The decrease in the porosity from 94.1% to 82.5% was related to an increase in Young's modulus to 5.2 kPa and 520 kPa, respectively, while the pore size decreased. Cell adhesion was possible on both types of scaffolds, but better conditions were provided by scaffolds with lower porosity, which was associated with an increase in fibre density.¹⁰⁰

Due to the properties of chitosan, it is a readily used biomaterial. In vitro and in vivo studies are conducted on the use of chitosan scaffolds in the treatment of damage to various tissues. The interactions and influence of CS on cells are investigated, among others, spinal cord⁵², bones, cartilage¹⁰¹, tendons¹⁰², skin¹⁰³.

The use of chitosan in the treatment of the spinal cord has been studied. The implants were inserted into the meninges or directly into the spinal cord for 6 or 12 months, respectively. The host cell response (rat) was low, which indicates the inert nature of chitosan and the possibility of using the material in long-term therapies.⁵² In search of chitosan with the best properties for the osteochondral treatment, porous chitosan scaffolds were prepared. *In vivo* studies indicate that the cellular response depended on the properties of the chitosan used, and chitosan with a DD of 83%, a relatively low molecular weight of 11.49 KDa and a high content of calcium, remaining due to the lack of demineralisation during the preparation, turned out to be the best for applications. After implant placement, its degradation and shaping of the subchondral bone were observed.¹⁰¹

Active layers can be applied to the scaffolds to improve the interaction at the biomaterial-tissue interface.¹⁰⁴ The surface of the chitosan scaffolds was mineralised to obtain apatite layers imitating bone. After modification, the scaffolds are characterised by greater rigidity and smaller pore sizes, yet sufficiently large to allow unhindered migration of bone cells.¹⁰⁵ The conducted *in vitro* studies indicate that the scaffold after apatite modification supports the adhesion and proliferation of cells to a greater extent than the unmodified version. Mineralised scaffolds are better suited for use in bone tissue engineering.^{106,107}

The cultivation of chondrocyte cells is aided by the use of porous chitosan microspheres (porosity ~90%, pore size 5 – 60 μm) with diameters of 180 – 280 μm ¹⁰⁸ and CS fibres with diameters between 4 and 22 μm . The fibres maintained the viability of chondrocytes (over 85%) and supported the formation of the extracellular matrix (ECM). However, it was concluded that reducing the size and the use of nanofibers could improve interactions with chondrocytes.¹⁰⁹

Chitosan as a scaffold surface modifier

Chitosan is often used as a coating material for implants or scaffolds. Such surface modification significantly improves the surface properties of an implant – its bioactivity, biocompatibility, corrosion resistance, as well as, properties supporting bone regeneration, such as osteoconductivity.¹¹⁰ Chitosan layers are stable, and depending on the concentration of chitosan, its molecular weight, the degree of deacetylation and application technique, they degrade at different rates, even allowing for long-term use.^{111,112}

Surface modification significantly influences the mechanical properties of the scaffolding. Three-dimensional, porous scaffolds made of polycaprolactam (PCL) were covered with layers of chitosan at various concentrations, from 1% to 3%. As the concentration of chitosan in the layer increases, the compression strength and the compression modulus factor increase, while scaffolding crystallinity decreases. The increase in the first two is likely related to the increase in the amount of amine groups that support PCL and improve the strength of the scaffold. The decrease in crystallinity is a result of the formation of hydrogen bonds between PCL and chitosan. Among the examined, the best osteoblast differentiation was provided by the PCL scaffold covered with a 2.5% chitosan layer.¹¹³

It is commonly known that the hydrophilicity/hydrophobicity of the scaffold affects cell adhesion and proliferation. Polylactide (PLA) is a polymer readily used in tissue engineering due to its biocompatibility and bioresorbability. It is however, a hydrophobic polymer that does not promote cell adhesion. In order to increase the hydrophilicity of the polymer, the PLA surface can be modified by applying a layer of chitosan.¹¹⁴ Modification of poly-*L*- lactide surface with chitosan also improves mechanical properties of the scaffold, as well as improves adhesion, differentiation, activity, and morphology of chondrocyte cells¹¹⁵ and mouse bone marrow stromal cells (mBMSCs) compared to the unmodified structure, which accelerates the bone regeneration process.^{51,116} The introduction of the PLLA scaffold with a CS layer into skull defects of rats and the examination of bone changes after 12 weeks showed that the modified scaffolds support greater growth of bone tissue with higher density compared to the unmodified ones. This confirms the suspicions that chitosan-coated polylactide scaffolds are sustainable for bone regeneration,¹¹⁶ and modifying the scaffold surface with chitosan significantly improves osteoblast adhesion and proliferation.¹¹⁷

Chitosan surfaces exhibit antimicrobial properties, highly desirable in biomedical applications. The antibacterial nature of CS was tested on Gram-negative strains of *E. coli*^{118,119} and Gram positive *Staphylococcus aureus*.¹²⁰ For both groups, the use of chitosan layers reduced bacterial settling.

In addition to applying layers of chitosan itself, layers of mixtures of chitosan and other compounds are also used to improve certain properties. The use of a chitosan layer with ZnO particles on a titanium implant increases the compatibility of such an implant and its corrosion resistance, which results from the closure of pores on the implant surface. The introduction of the oxide improves the antibacterial properties of the layer compared to the layer made of chitosan itself.¹¹⁹ Antibiotics can also be incorporated into the chitosan layer. The compounds bind through weak intermolecular interactions, which allows easy release of the antibiotic and, consequently, the fight against bacteria.¹²¹

Complexes with other natural polymers

Due to the cationic nature of the polymer, CS has the ability to spontaneously form stable polyelectrolyte complexes (PEC) with negatively charged structures such as natural polymers. In solution, permanent electrostatic interactions are formed between the cationic amino group of chitosan and the negatively charged group of the polyanion. Complexes are formed in stages, first the primary complex is formed, with chains of polyions randomly arranged in space. Then the chains arrange themselves in orderly structures, which is associated with the formation of hydrogen bonds, van der Waals forces and others. Concurrently, aggregation into various structures may take place. The wide range of properties, as well as the non-toxicity, biodegradability and biocompatibility of PEC ensure a wide application of the complexes, especially in tissue engineering.^{122,123} Examples of PEC are shown in Table 2. PEC formation can be investigated, for example, by FTIR (N-H, C=O bond shift study), DSC differential scanning calorimetry (melting point shift) or by examining changes in zeta potential.

The formation of complexes is influenced by the concentration of polymers, the mass ratio of polyelectrolytes, the order of polymer addition, the degree of CS deacetylation, the pH value of the solution, presence of other ions and molecules in the solution. As the concentration of polymers in the solution increases, the size of the particles formed increases. In turn, the mass ratio of the polymers used affects the size, charge and solubility of resulting complexes.^{124,125} The molecular weight of chitosan and the degree of deacetylation affect the size of the complex. The larger the polymer, the thinner the packing of the compound and the larger the

size of the PEC.³⁹ Other molecules or ions than the polymers forming the complex may be present in the solution. They affect the ease of formation of complexes, their stability and properties. An example of such a compound is sodium lauryl sulphate surfactant, the use of which increases the surface roughness and the thickness of the chitosan/alginate (CS/Alg).^{125,126}

The size of the nanoparticles of the chitosan CS/Pc with pectin complex varied depending on the order of addition of polymers. At low polymer concentrations, larger particles were formed when chitosan was added first, the inverse was true at high concentrations. The size of the complexes ranged from 460 nm (low polymer concentration) to 1110 nm (high polymer concentration). The zeta potential depends on the mass ratio of the polymers used, for complexes with different mass ratios it was in the range between 40 and 60 mV, and the advantage of chitosan in the complex increases the value of the potential, i.e. the stability of the complex. CS/Pc nanocomplexes are characterised by low stability compared to other polyelectrolyte complexes, they lose their stability after 14 days, and they degrade after 30 days. The stability is independent of particle size, but is dependent on the pH of the solution (stable at pH 3.5 – 6.0).¹²⁴

The introduction of a polyanion into a chitosan scaffold has many advantages. The electrostatic interaction between the polymers increases the stability of the scaffolds obtained.¹²⁷ Modification with alginate improves the mechanical properties of the scaffold, the compressive modulus and yield strength after the modification are, respectively, 8.16 MPa and 0.46 MPa, for the chitosan only scaffold these values are about three times lower. Also, the preparation of the scaffold from the complex is simpler, since the environment is not necessarily acidic, it can just as well be alkaline or neutral. The chitosan/alginate complex is non-toxic, has anti-inflammatory effects,¹²⁸ in many cases supports adhesion, as well as osteoblast proliferation and angiogenesis.¹²⁹ However, some sources report the CS/Alg surface as unfavourable for cell adhesion.⁴³

Composites with chitosan

Often, implants made of purely natural or synthetic polymers do not have the mechanical properties desired in tissue engineering, for instance, they are not able to carry the required loads.¹³ To change the properties of the scaffold, a new compound can be introduced into the starting composition to obtain a composite. Examples of complexes are presented in Table 3. The use of the composite influences morphology, mechanical properties, porosity, swelling of the scaffolds as well as biomineralisation and degradation processes. Chitosan is a modifier commonly used in composites, a building material popular in the animal world, composites of which support bone regeneration processes such as adhesion and proliferation of bone cells, osteocalcin secretion or biomineralisation.^{138–140} On the other hand, nanoparticles are readily introduced into chitosan scaffolds, thanks to which biomineralisation takes place more efficiently and the degradation rate decreases.

The morphology of the scaffolds significantly depends on the concentrations of the polymers used. For the poly-L-lactide + chitosan (PLLA+CS) scaffold, the higher the concentration of chitosan in the starting solution, the more chitosan was deposited on the pore surface, making the pores surface more jagged compared to polylactide systems alone, which is desirable due to an increase in the surface of the implant.¹³⁹

The use of the PLLA+CS composite significantly affects the rate of scaffold degradation in comparison to the polylactide scaffold. This is explained by the fact that when PLLA hydrolyses into lactic acid, it lowers the pH of the environment, which causes the dissolution of the CS. In this way, along with the depletion of chitosan, the pores of the scaffold increase, which increases its surface contact with water. Also, the hydrophilic properties of chitosan accelerate the diffusion of water into the interior, making hydrolysis of the hydrophobic polylactide faster.⁹²

The use of composites has a significant influence on mechanical properties. In order to strengthen the macro-spheres made of chitosan, montmorillonite (MMT) and/or hydroxyapatite (HAP) were introduced into the system. Composite scaffoldings were characterised by much greater compressive strength. The introduction of MMT and HAP also reduced the swelling of scaffolds, which is probably related to the hydrophobicity of the additives and the binding of hydrophilic amino and hydroxyl CS groups by hydroxyapatite. Interactions with bone cells and cell proliferation supported all systems.¹⁴¹

The chitosan/collagen polyelectrolyte complex (CS/Coll) was enriched with MMT and modified organomontmorillonite (OMMT). The scaffolds made of PEC had weakly connected large pores (about 1 mm). The introduction of MMT and OMMT made it possible to obtain a structure with well connected pores of smaller diameters (200 – 400 μm for CS/Coll+MMT and 50 – 200 μm for CS/Coll+OMMT), which are better suited for seeding cells. Both composites were characterised by lower swelling ratio, degradation rates and greater compressive strength, and they supported biomineralisation better than the CS/Coll complex.¹⁴²

The introduction of nanomaterials into scaffolds made of chitosan or its complexes affects the properties of the structures. The use of a chitosan-chitin composite with the addition of ZrO_2 nanoparticles (CS+CI+n ZrO_2) enables the production of non-toxic scaffolds with a pore size of 150 – 200 μm (larger in the CS+CI system) and improved bioactivity.¹⁴³ Porous scaffolds made of a combination of chitosan, gelatine and hydroxyapatite (Cs+Ge+nHAP composite) with an average pore size of 100 – 180 μm support the adhesion and development of bone cells. Hydroxyapatite occurs naturally in human bones, while gelatine and chitosan mimic the extracellular matrix (ECM) well. The introduction of nHAP significantly affects the properties of the system, increases the susceptibility to mineralisation of the scaffold, and as a result, significantly improves cytocompatibility, reduces swelling and the rate of degradation. Composite scaffolds are well suited for bone tissue engineering.¹⁴⁴ In the same way, the properties of the Cs+Ge scaffolds change after the introduction of SiO_2 nanoparticles (Cs+Ge+n SiO_2 composite).¹⁴⁵

Cellular response to chitosan materials

After a scaffold is implanted, the body reacts, which ultimately leads to tissue reconstruction. The damage is immediately recognised and triggers appropriate interactions with blood, clot formation, cellular response, and eventually tissue reconstruction.¹⁵⁷ A thin layer of water forms on the scaffold surface, and proteins adhere to it. The bone cells then recognise these proteins and settle on the implant. Cell growth and integration enables tissue to regenerate on the scaffold surface.^{158,159} Depending on the surface chemistry and implant topography, cells may interact with the material with different intensity.

Cell adhesion

The term “adhesion” describes two phenomena that occur during the settlement of scaffolding. It concerns the short-term generation of interactions between the cell membrane and the material (ionic forces, van der Waals interactions) and long-term cell attachment.¹⁵⁹ Biomaterials may affect cell adhesion, be osteoconductive or osteoinductive. Osteoconduction is the ability of a material to connect to bone tissue, provide adequate support for cells and influence the direction of the regeneration process. The osteoconductive material also positively influences the processes of cell proliferation and ECM formation. Osteoinduction involves triggering a series of processes and reactions that lead to bone regeneration through the use of biomolecular signalling devices. One such process is, for example, cell differentiation.^{160–162}

Implants are recognised by the body as foreign bodies and trigger an immune response. The body’s response mechanism after implantation (Figure 3) begins with the formation of a thin layer of water on the surface of the biomaterial within a few nanoseconds. Then, adhesion proteins are deposited, these are peptides with a specific structure, containing the RGD group – the arginine-glycine-aspartic acid combination.^{163,164} Proteins are deposited on the implant surface within seconds to hours. Depending on the surface properties of the biomaterial, proteins settle in different amounts, densities and conformations.¹⁶⁵ The cells of the tissue then recognise the attached proteins, and cell-protein interactions are formed, which last from a few minutes to several days. Cell growth and integration, the final step, enables tissue formation on the scaffold surface.^{157,158}

In addition to the surface properties, the scaffold topography and porosity have a significant impact on cell adhesion. The rough structure increases the contact area between the implant and the surrounding tissue and allows cells to settle. Osteoblast differentiation is supported in particular by nanosized roughness.^{104,166} The scaffold should be characterised by open porosity, which enables cell migration and colonisation of pores. Open porosity supports the process of vascularisation of the resulting tissue.¹⁶⁰ Cell adhesion is significantly affected by the surface energy of the biomaterial. High surface energy enables very good wettability and

adhesion. Osteoblasts are more likely to settle, differentiate faster and multiply on a surface with higher surface energy.^{167–169}

Interaction with groups in chitosan

The biomaterial can interact with the body's cells in different ways. Significant surface features that influence this are surface properties such as hydrophilicity, the presence of functional groups or surface charge.^{104,130}

Functional groups on the surface of the biomaterial significantly affect the adhesion of bone cells. The binding of osteoblasts to surfaces with different functional groups was investigated. The hydroxyl–OH and amino–NH₂ groups present in chitosan supported the adhesion and differentiation of stem cells into osteoblasts better than the carboxyl –COOH and methyl–CH₃ groups.¹⁷⁰ Stem cell subsidence was most strongly supported by the amino group. Depending on the functional groups, the shape of the cells may also change. Flattened cells were preferred for the –NH₂ group, and spherical cells for –COOH.¹⁷¹ The surfaces with the amino group also promoted and maintained the process of osteogenesis, both under normal and osteogenesis-promoting conditions.¹⁷²

The wettability of the biomaterial affects the adhesion of cells. Good wettability facilitates the process of proteins settling on the surface of the material and, as a result, cell adhesion. A greater number of adhesive proteins, and a smaller number of hydrophobic proteins that do not participate in the process, were deposited on the hydrophilic surfaces.^{163,173}

Proteins settle differently on the positively charged surface than on the negatively charged one. Amino groups of the CS promote the deposition of negatively charged proteins and cell membranes, proliferation and differentiation, which results from electrostatic interactions.¹⁵⁹

Chitosan with a higher degree of deacetylation provides better conditions for osteoblast subsidence, but to a lesser extent supports the secretion of osteoprotegerin compared to CS with a lower degree of deacetylation.^{161,174,175}

Secreted cellular metabolites

There are several types of cells in bone: osteoblasts, osteocytes, osteoclasts, and there are also bone lining cells.¹⁷⁶ Osteoblasts are mature, metabolically active bone-building cells that are found at the surface of the bone. The task of osteoblasts is to secrete compounds that make up the intercellular substance.^{177,178} The most numerous cells in bone tissue (over 90%¹⁷⁹) are bone cells – osteocytes. They arise from transformed osteoblasts trapped in the bone matrix, in the bone cavities. Osteocytes form a communication network of bone cells, thanks to which they regulate bone tissue homeostasis. Signals are sent via cleft junctions, chemical secretion, or direct dendrite association.^{180–182} The bone lining cells are osteoblasts that have not undergone apoptosis or developed into osteocytes. They perform functions related to bone remodelling.^{176,183} The last group of cells are multinucleated osteoclasts, whose task is to maintain the calcium balance in the tissue and to secrete compounds that break down the bone.^{184–187}

The living cells of the body conduct metabolic processes to produce the energy necessary for life from carbohydrates, proteins and fats. For this, the energy carrier adenosine-5'-triphosphate (ATP), produced in various processes, is most often used. Glucose is the main source of energy in mesenchymal stem cells, which is converted into pyruvic acid and ATP in the process of glycolysis. Osteoblasts obtain ATP through glycolysis and the Krebs cycle, with predominance of the former process. The Krebs cycle is used mainly in the period of higher energy demand, during bone formation. In addition to glucose, osteoblasts obtain ATP from the transformation of amino acids (in particular glutamine) and fats. Osteocyte metabolism is not a well understood process. Osteoclasts generate energy in the processes of glycolysis and the Krebs cycle.¹⁸⁸

The extracellular matrix is mostly produced by osteoblasts. Osteocytes contribute to a lesser extent to the production of matrix, which is due to their structure – mature osteocytes do not have many organelles responsible for secretion.¹⁸² ECM consists mainly of collagen (90%) and non-collagen proteins (10%). The vast majority of collagen is type I collagen, however, type III and V are also found in the ECM. The non-

collagenous organic part consists of proteoglycans, osteocalcin (also known as bone gamma-carboxyglutamic acid-containing protein (BGLAP)), glycoproteins and Small Integrin-Binding LIgand N-linked Glycoproteins (SIBLINGs).^{189–191} Proteoglycans are proteins with which saccharide glycosaminoglycans (GAGs) are linked. They are mainly secreted by osteoblasts, e.g. biglikan¹⁹² or decorin.¹⁹³ Osteocalcin is secreted mainly by mature osteoblasts, but also by osteocytes.¹⁹⁴ SIBLINGs are small hydrophilic proteins that contain the same set of amino acids (Arg-Gly-Asp) found in the bone matrix. These compounds are mainly produced by osteocytes (Matrix Extracellular Phosphoglycoprotein¹⁹⁵), but to a lesser extent also by osteoblasts (osteopontin, Dentin Matrix Protein-1^{196,197}).¹⁹⁸

Osteoclasts are capable of secreting H^+ -adenosine triphosphate responsible for the dissolution and cathepsin K protease responsible for dissolving the demineralised organic part.^{199,200}

Chitosan has a positive effect on the metabolic behaviour of cells. In vitro studies of MCF-7 cells on chitosan scaffolds were performed. The metabolism of cells in such a system is very similar to that in tissue, which proves the positive effect of the chitosan matrix on the vital processes of cells.²⁰¹ Similarly, for dental pulp stromal cells, CS has a positive effect on metabolism and proliferation.²⁰²

CONCLUSION

Chitosan, a chitin derivative, is a unique polysaccharide. It is obtained in the process of deacetylation of chitin, most often derived from the shells of sea crustaceans. It is a readily used compound in tissue engineering due to its similarity to the glycosaminoglycans present in the body, biocompatibility, bioactivity, non-toxicity, antibacterial properties and non-toxic degradation products that may occur under the influence of human enzymes. Amine groups of chitosan improve the surface properties and provide better adhesion of bone cells. CS can be used in the production of cell scaffolds for bone regeneration as a direct substrate or component of a composite. The cationic nature of the polysaccharide also enables the formation of polyelectrolyte complexes with other natural polymers. It can also be used for surface modification to improve the properties of the scaffold.

AUTHOR INFORMATION

Corresponding Author

*Email: agnieszka.gajadhur@pw.edu.pl

Author Contributions

The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.

Funding Sources

This scientific research was financed from the National Centre for Research and Development as a research project “Lider 11” (LIDER/4/0010/L-11/19/NCBR/2020) titled “Porous, biodegradable implants for the regeneration of spongy bone”.

Notes

The authors declare no competing financial interest. Thanks to Karolina Kalbarczyk for help with graphics.

ABBREVIATIONS

Alg, alginate;

ATP, adenosine triphosphate;

BCNs, bacterial cellulose nanocrystals;

BGLAP, bone gamma-carboxyglutamic acid-containing protein;

CHAP, carbonated hydroxyapatite;

CI, chitin;
 Coll, collagen;
 CS, chitosan;
 CSA, chondroitin sulfate;
 DSC, differential scanning calorimetry;
 ECM, extracellular matrix;
 FTIR, fourier transform infrared spectroscopy;
 GAGs, glycosaminoglycans;
 Ge, gelatin;
 HA, hyaluronic acid
 HAP, hydroxyapatite;
 MMT, montmorillonite;
 nBG, nanobioglass;
 nHAP, nano hydroxyapatite;
 nPP, nano-pearl powder;
 nSiO₂, nano-silica;
 OMMT, organomontmorillonite;
 Pc, pectin;
 PCL, polycaprolactone
 PCS, phosphorylated chitosan;
 PEC, polyelectrolyte complex;
 PGS, polyglycerol sebacate;
 PLLA, poly-L-lactide;
 PVA, poly(vinyl alcohol);
 SIBLINGS, Small Integrin-Binding LIgand N-linked Glycoproteins;

REFERENCES

- (1) Alonzo, M.; Alvarez Primo, F.; Anil Kumar, S.; Mudloff, J. A.; Dominguez, E.; Fregoso, G.; Ortiz, N.; Weiss, W. M.; Joddar, B. Bone Tissue Engineering Techniques, Advances, and Scaffolds for Treatment of Bone Defects. *Curr. Opin. Biomed. Eng.* **2021** , *17*(August 2020), 100248. <https://doi.org/10.1016/j.cobme.2020.100248>.
- (2) Kanczler, J. M.; Wells, J. A.; Gibbs, D. M. R.; Marshall, K. M.; Tang, D. K. O.; Oreffo, R. O. C. *Bone Tissue Engineering and Bone Regeneration* ; INC, 2020. <https://doi.org/10.1016/B978-0-12-818422-6.00052-6>.
- (3) Schemitsch, E. H. Size Matters: Defining Critical in Bone Defect Size! *J. Orthop. Trauma* **2017** , *31* (10), S20–S22. <https://doi.org/10.1097/BOT.0000000000000978>.

- (4) Kozusko, S. D.; Riccio, C.; Goulart, M.; Bumgardner, J.; Jing, X. L.; Konofaos, P. Chitosan as a Bone Scaffold Biomaterial. *J. Craniofac. Surg.* **2018** , *29* (7), 1788–1793. <https://doi.org/10.1097/SCS.0000000000004909>.
- (5) Giannoudis, P. V.; Dinopoulos, H.; Tsiridis, E. Bone Substitutes: An Update. *Injury* **2005** , *36 Suppl 3* , 20–27. <https://doi.org/10.1016/j.injury.2005.07.029>.
- (6) Pape, H. C.; Evans, A.; Kobbe, P. Autologous Bone Graft: Properties and Techniques. *J. Orthop. Trauma* **2010** , *24* (SUPPL. 1), 36–40. <https://doi.org/10.1097/BOT.0b013e3181cec4a1>.
- (7) Preethi Soundarya, S.; Haritha Menon, A.; Viji Chandran, S.; Selvamurugan, N. Bone Tissue Engineering: Scaffold Preparation Using Chitosan and Other Biomaterials with Different Design and Fabrication Techniques. *Int. J. Biol. Macromol.* **2018** , *119* , 1228–1239. <https://doi.org/10.1016/j.ijbiomac.2018.08.056>.
- (8) Deb, P.; Deoghare, A. B.; Borah, A.; Barua, E.; Das Lala, S. Scaffold Development Using Biomaterials: A Review. *Mater. Today Proc.* **2018** , *5* (5), 12909–12919. <https://doi.org/10.1016/j.matpr.2018.02.276>.
- (9) Hudecki, A.; Kiryczyński, G.; Los, M. J. Biomaterials, Definition, Overview. *Stem Cells Biomater. Regen. Med.* **2018** , No. ii, 85–98. <https://doi.org/10.1016/B978-0-12-812258-7.00007-1>.
- (10) Budnicka, M.; Szymaniak, M.; Kołbuk, D.; Ruśkowski, P.; Gadomska-Gajadur, A. Biomineralization of Poly-L-Lactide Spongy Bone Scaffolds Obtained by Freeze-Extraction Method. *J. Biomed. Mater. Res. - Part B Appl. Biomater.* **2020** , *108* (3), 868–879. <https://doi.org/10.1002/jbm.b.34441>.
- (11) Navarro, M.; Michiardi, A.; Castaño, O.; Planell, J. A. Biomaterials in Orthopaedics. *J. R. Soc. Interface* **2008** , *5* (27), 1137–1158. <https://doi.org/10.1098/rsif.2008.0151>.
- (12) Larry L, H.; Julia M, P. Third-Generation Biomedical Materials. *Science (80-.)*. **2002** , *295* (February), 1014–1017.
- (13) Islam, M. M.; Shahruzzaman, M.; Biswas, S.; Nurus Sakib, M.; Rashid, T. U. Chitosan Based Bioactive Materials in Tissue Engineering Applications-A Review. *Bioact. Mater.* **2020** , *5* (1), 164–183. <https://doi.org/10.1016/j.bioactmat.2020.01.012>.
- (14) Lalzawmliana, V.; Anand, A.; Mukherjee, P.; Chaudhuri, S.; Kundu, B.; Nandi, S. K.; Thakur, N. L. Marine Organisms as a Source of Natural Matrix for Bone Tissue Engineering. *Ceram. Int.* **2019** , *45* (2), 1469–1481. <https://doi.org/10.1016/j.ceramint.2018.10.108>.
- (15) Bastiaens, L.; Soetemans, L.; D'Hondt, E.; Elst, K. Sources of Chitin and Chitosan and Their Isolation. *Chitin and Chitosan* **2019** , 1–34. <https://doi.org/10.1002/9781119450467.ch1>.
- (16) Zargar, V.; Asghari, M.; Dashti, A. A Review on Chitin and Chitosan Polymers: Structure, Chemistry, Solubility, Derivatives, and Applications. *ChemBioEng Rev.* **2015** , *2* (3), 204–226. <https://doi.org/10.1002/cben.201400025>.
- (17) Wang, W.; Xue, C.; Mao, X. Chitosan: Structural Modification, Biological Activity and Application. *Int. J. Biol. Macromol.* **2020** , *164* , 4532–4546. <https://doi.org/10.1016/j.ijbiomac.2020.09.042>.
- (18) Yadav, M.; Goswami, P.; Paritosh, K.; Kumar, M.; Pareek, N.; Vivekanand, V. Seafood Waste: A Source for Preparation of Commercially Employable Chitin/Chitosan Materials. *Bioresour. Bioprocess.* **2019** , *6* (1). <https://doi.org/10.1186/s40643-019-0243-y>.
- (19) Bakshi, P. S.; Selvakumar, D.; Kadirvelu, K.; Kumar, N. S. Chitosan as an Environment Friendly Biomaterial – a Review on Recent Modifications and Applications. *Int. J. Biol. Macromol.* **2020** , *150* , 1072–1083. <https://doi.org/10.1016/j.ijbiomac.2019.10.113>.
- (20) Pochanavanich, P.; Suntornsuk, W. Fungal Chitosan Production and Its Characterization. *Lett. Appl. Microbiol.* **2002** , *35* (1), 17–21. <https://doi.org/10.1046/j.1472-765X.2002.01118.x>.

- (21) Kou, S. (Gabriel); Peters, L. M.; Mucalo, M. R. Chitosan: A Review of Sources and Preparation Methods. *Int. J. Biol. Macromol.* **2021** , 169 , 85–94. <https://doi.org/10.1016/j.ijbiomac.2020.12.005>.
- (22) Younes, I.; Rinaudo, M. Chitin and Chitosan Preparation from Marine Sources. Structure, Properties and Applications. *Mar. Drugs* **2015** , 13 (3), 1133–1174. <https://doi.org/10.3390/md13031133>.
- (23) Kumari, S.; Kishor, R. *Chitin and Chitosan: Origin, Properties, and Applications* ; INC, 2020. <https://doi.org/10.1016/b978-0-12-817970-3.00001-8>.
- (24) Younes, I.; Hajji, S.; Frachet, V.; Rinaudo, M.; Jellouli, K.; Nasri, M. Chitin Extraction from Shrimp Shell Using Enzymatic Treatment. Antitumor, Antioxidant and Antimicrobial Activities of Chitosan. *Int. J. Biol. Macromol.* **2014** , 69 , 489–498. <https://doi.org/10.1016/j.ijbiomac.2014.06.013>.
- (25) Arbia, W.; Arbia, L.; Adour, L.; Amrane, A. Chitin Extraction from Crustacean Shells Using Biological Methods – A Review. *Food Technol. Biotechnol* **2013** , 51 (1), 12–25.
- (26) Valdez-Peña, A. U.; Espinoza-Perez, J. D.; Sandoval-Fabian, G. C.; Balagurusamy, N.; Hernandez-Rivera, A.; de-la-Garza-Rodriguez, I. M.; Contreras-Esquivel, J. C. Screening of Industrial Enzymes for Deproteinization of Shrimp Head for Chitin Recovery. *Food Sci. Biotechnol.* **2010** , 19 (2), 553–557. <https://doi.org/10.1007/s10068-010-0077-z>.
- (27) Doan, C. T.; Tran, T. N.; Nguyen, V. B.; Vo, T. P. K.; Nguyen, A. D.; Wang, S. L. Chitin Extraction from Shrimp Waste by Liquid Fermentation Using an Alkaline Protease-Producing Strain, *Brevibacillus Parabrevis*. *Int. J. Biol. Macromol.* **2019** , 131 , 706–715. <https://doi.org/10.1016/j.ijbiomac.2019.03.117>.
- (28) Aravamudhan, A.; Ramos, D. M.; Nada, A. A.; Kumbar, S. G. *Natural Polymers: Polysaccharides and Their Derivatives for Biomedical Applications* ; Elsevier Inc., 2014. <https://doi.org/10.1016/B978-0-12-396983-5.00004-1>.
- (29) Xu, H.; Yang, Y. 3D Electrospun Fibrous Structures from Biopolymers. *ACS Symp. Ser.* **2014** , 1175 , 103–126. <https://doi.org/10.1021/bk-2014-1175.ch007>.
- (30) Tsai, H.-S.; Wang, Y.-Z.; Lin, J.-J.; Lien, W.-F. Preparation and Properties of Sulfopropyl Chitosan Derivatives with Various Sulfonation Degree. *Wiley Interisci.* **2009** . <https://doi.org/DOI.10.1002/app.31689>.
- (31) Grant, J.; Allen, C. Chitosan as a Biomaterial for Preparation of Depot-Based Delivery Systems. *ACS Symp. Ser.* **2006** , 934 , 201–205. <https://doi.org/10.1021/bk-2006-0934.ch010>.
- (32) Lu, S.; Song, X.; Cao, D.; Chen, Y.; Yao, K. Preparation of Water-Soluble Chitosan. *J. Appl. Polym. Sci.* **2004** , 91 (6), 3497–3503. <https://doi.org/10.1002/app.13537>.
- (33) Leedy, M. R.; Martin, H. J.; Norowski, P. A.; Jennings, J. A.; Haggard, W. O.; Bumgardner, J. D. Use of Chitosan as a Bioactive Implant Coating for Bone-Implant Applications. *Adv. Polym. Sci.* **2011** , 244 (1), 129–166. https://doi.org/10.1007/12_2011_115.
- (34) Chicatun, F.; Griffanti, G.; McKee, M. D.; Nazhat, S. N. *Collagen/Chitosan Composite Scaffolds for Bone and Cartilage Tissue Engineering* , Second Edi.; Elsevier Ltd., 2017. <https://doi.org/10.1016/b978-0-08-100752-5.00008-1>.
- (35) Kumar, M. N. V. R.; Muzzarelli, R. A. A.; Muzzarelli, C.; Sashiwa, H.; Domb, A. J. Chitosan Chemistry and Pharmaceutical Perspectives. *Chem. Rev.* **2004** , 104 (12), 6017–6084. <https://doi.org/10.1021/cr030441b>.
- (36) Raquel Madureira, A.; Sarmiento, B.; Pintado, M. Current State of the Potential Use of Chitosan as Pharmaceutical Excipient. *Handb. Polym. Pharm. Technol.* **2015** , 3 , 275–297. <https://doi.org/10.1002/9781119041450.ch9>.
- (37) Wan, Y.; Fang, Y.; Wu, H.; Cao, X. Porous Polylactide/Chitosan Scaffolds for Tissue Engineering. *J. Biomed. Mater. Res. - Part A* **2007** , 80 (4), 776–789. <https://doi.org/10.1002/jbm.a.31025>.

- (38) Antunes, J. C.; Pereira, C. L.; Molinos, M.; Ferreira-Da-Silva, F.; Dessi, M.; Gloria, A.; Ambrosio, L.; Goncalves, R. M.; Barbosa, M. A. Layer-by-Layer Self-Assembly of Chitosan and Poly(γ -Glutamic Acid) into Polyelectrolyte Complexes. *Biomacromolecules* **2011** ,12 (12), 4183–4195. <https://doi.org/10.1021/bm2008235>.
- (39) Strand, S. P.; Danielsen, S.; Christensen, B. E.; Vårum, K. M. Influence of Chitosan Structure on the Formation and Stability of DNA-Chitosan Polyelectrolyte Complexes. *Biomacromolecules* **2005** , 6 (6), 3357–3366. <https://doi.org/10.1021/bm0503726>.
- (40) Maurstad, G.; Danielsen, S.; Stokke, B. T. The Influence of Charge Density of Chitosan in the Compaction of the Polyanions DNA and Xanthan. *Biomacromolecules* **2007** , 8 (4), 1124–1130. <https://doi.org/10.1021/bm0610119>.
- (41) Kaczmarek, B.; Sionkowska, A.; Gołyńska, M.; Polkowska, I.; Szponder, T.; Nehrbass, D.; Osyczka, A. M. In Vivo Study on Scaffolds Based on Chitosan, Collagen, and Hyaluronic Acid with Hydroxyapatite. *Int. J. Biol. Macromol.* **2018** , 118 , 938–944. <https://doi.org/10.1016/j.ijbiomac.2018.06.175>.
- (42) Wang, J. Z.; Huang, X. B.; Xiao, J.; Yu, W. T.; Wang, W.; Xie, W. Y.; Zhang, Y.; Ma, X. J. Hydro-Spinning: A Novel Technology for Making Alginate/Chitosan Fibrous Scaffold. *J. Biomed. Mater. Res. - Part A* **2010** , 93 (3), 910–919. <https://doi.org/10.1002/jbm.a.32590>.
- (43) Phoeung, T.; Spanedda, M. V.; Roger, E.; Heurtault, B.; Fournel, S.; Reisch, A.; Mutschler, A.; Perrin-Schmitt, F.; Hemmerlé, J.; Collin, D.; et al. Alginate/Chitosan Compact Polyelectrolyte Complexes: A Cell and Bacterial Repellent Material. *Chem. Mater.* **2017** ,29 (24), 10418–10425. <https://doi.org/10.1021/acs.chemmater.7b03863>.
- (44) Park, J. W.; Park, K. H.; Seo, S. Natural Polyelectrolyte Complex-Based PH-Dependent Delivery Carriers Using Alginate and Chitosan. *J. Appl. Polym. Sci.* **2019** , 136 (43), 1–7. <https://doi.org/10.1002/app.48143>.
- (45) Lallana, E.; Rios De La Rosa, J. M.; Tirella, A.; Pelliccia, M.; Gennari, A.; Stratford, I. J.; Puri, S.; Ashford, M.; Tirelli, N. Chitosan/Hyaluronic Acid Nanoparticles: Rational Design Revisited for RNA Delivery. *Mol. Pharm.* **2017** , 14 (7), 2422–2436. <https://doi.org/10.1021/acs.molpharmaceut.7b00320>.
- (46) Oyarzun-Ampuero, F. A.; Brea, J.; Loza, M. I.; Torres, D.; Alonso, M. J. Chitosan-Hyaluronic Acid Nanoparticles Loaded with Heparin for the Treatment of Asthma. *Int. J. Pharm.* **2009** , 381(2), 122–129. <https://doi.org/10.1016/j.ijpharm.2009.04.009>.
- (47) Gennari, A.; de la Rosa, J. M. R.; Hohn, E.; Pelliccia, M.; Lallana, E.; Donno, R.; Tirella, A.; Tirelli, N. The Different Ways to Chitosan/Hyaluronic Acid Nanoparticles: Templated vs Direct Complexation. Influence of Particle Preparation on Morphology, Cell Uptake and Silencing Efficiency. *Beilstein J. Nanotechnol.* **2019** , 10 , 2594–2608. <https://doi.org/10.3762/bjnano.10.250>.
- (48) Pandey, S.; Mishra, A.; Raval, P.; Patel, H.; Gupta, A.; Shah, D. Chitosan-Pectin Polyelectrolyte Complex as a Carrier for Colon Targeted Drug Delivery. *J. Young Pharm.* **2013** , 5 (4), 160–166. <https://doi.org/10.1016/j.jyp.2013.11.002>.
- (49) Bombaldi de Souza, F. C.; Bombaldi de Souza, R. F.; Drouin, B.; Mantovani, D.; Moraes, Â. M. Comparative Study on Complexes Formed by Chitosan and Different Polyanions: Potential of Chitosan-Pectin Biomaterials as Scaffolds in Tissue Engineering. *Int. J. Biol. Macromol.* **2019** , 132 , 178–189. <https://doi.org/10.1016/j.ijbiomac.2019.03.187>.
- (50) Kumar, M.; Brar, A.; Vivekanand, V.; Pareek, N. *Possibilities and Perspectives of Chitosan Scaffolds and Composites for Tissue Engineering* ; Elsevier Inc., 2019. <https://doi.org/10.1016/B978-0-12-816909-4.00007-5>.
- (51) Li, M.; Mondrinos, M. J.; Chen, X.; Gandhi, M. R.; Ko, F. K.; Lelkes, P. I. Fabrication and Characterization of PLLA–Chitosan Hybrid Scaffolds with Improved Cell Compatibility. *J. Biomed. Mater. Res. Part*

A **2006** , 79 (4), 963–973. <https://doi.org/10.1002/jbm.a>.

(52) Kim, H.; Tator, C. H.; Shoichet, M. S. Chitosan Implants in the Rat Spinal Cord: Biocompatibility and Biodegradation. *J. Biomed. Mater. Res. - Part A* **2011** , 97 A (4), 395–404. <https://doi.org/10.1002/jbm.a.33070>.

(53) Luo, K.; Yin, J.; Khutoryanskaya, O. V.; Khutoryanskiy, V. V. Mucoadhesive and Elastic Films Based on Blends of Chitosan and Hydroxyethylcellulose. *Macromol. Biosci.* **2008** , 8(2), 184–192. <https://doi.org/10.1002/mabi.200700185>.

(54) Wu, Q. X.; Lin, D. Q.; Yao, S. J. Design of Chitosan and Its Water Soluble Derivatives-Based Drug Carriers with Polyelectrolyte Complexes. *Mar. Drugs* **2014** , 12 (12), 6236–6253. <https://doi.org/10.3390/md12126236>.

(55) Yuan, X.; Zheng, J.; Jiao, S.; Cheng, G.; Feng, C.; Du, Y.; Liu, H. A Review on the Preparation of Chitosan Oligosaccharides and Application to Human Health, Animal Husbandry and Agricultural Production. *Carbohydr. Polym.* **2019** , 220 (February), 60–70. <https://doi.org/10.1016/j.carbpol.2019.05.050>.

(56) Shi, G. N.; Zhang, C. N.; Xu, R.; Niu, J. F.; Song, H. J.; Zhang, X. Y.; Wang, W. W.; Wang, Y. M.; Li, C.; Wei, X. Q.; et al. Enhanced Antitumor Immunity by Targeting Dendritic Cells with Tumor Cell Lysate-Loaded Chitosan Nanoparticles Vaccine. *Biomaterials* **2017** , 113 , 191–202. <https://doi.org/10.1016/j.biomaterials.2016.10.047>.

(57) Abd El-Hack, M. E.; El-Saadony, M. T.; Shafi, M. E.; Zabermaawi, N. M.; Arif, M.; Batiha, G. E.; Khafaga, A. F.; Abd El-Hakim, Y. M.; Al-Sagheer, A. A. Antimicrobial and Antioxidant Properties of Chitosan and Its Derivatives and Their Applications: A Review. *Int. J. Biol. Macromol.* **2020** , 164 , 2726–2744. <https://doi.org/10.1016/j.ijbiomac.2020.08.153>.

(58) Duan, C.; Meng, X.; Meng, J.; Khan, M. I. H.; Dai, L.; Khan, A.; An, X.; Zhang, J.; Huq, T.; Ni, Y. Chitosan as A Preservative for Fruits and Vegetables: A Review on Chemistry and Antimicrobial Properties. *Chitosan as A Preserv. Fruits Veg. A Rev. Chem. Antimicrob. Prop.* **2019** , 4 (1), 11–21. <https://doi.org/10.21967/jbb.v4i1.189>.

(59) Kucharska, M.; Sikora, M.; Brzoza-Malczyńska, K.; Owczarek, M. Antimicrobial Properties of Chitin and Chitosan. *Chitin and Chitosan* **2019** , 169–187. <https://doi.org/10.1002/9781119450467.ch7>.

(60) Kim, J.-S.; Shin, D.-H. Inhibitory Effect on Streptococcus Mutans and Mechanical Properties of the Chitosan Containing Composite Resin. *Restor. Dent. Endod.* **2013** , 38 (1), 36. <https://doi.org/10.5395/rde.2013.38.1.36>.

(61) Raafat, D.; Von Bargen, K.; Haas, A.; Sahl, H. G. Insights into the Mode of Action of Chitosan as an Antibacterial Compound. *Appl. Environ. Microbiol.* **2008** , 74 (12), 3764–3773. <https://doi.org/10.1128/AEM.00453-08>.

(62) Helander, I. M.; Nurmiäho-Lassila, E. L.; Ahvenainen, R.; Rhoades, J.; Roller, S. Chitosan Disrupts the Barrier Properties of the Outer Membrane of Gram-Negative Bacteria. *Int. J. Food Microbiol.* **2001** , 71 (2–3), 235–244. [https://doi.org/10.1016/S0168-1605\(01\)00609-2](https://doi.org/10.1016/S0168-1605(01)00609-2).

(63) Ahmad, S. I.; Ahmad, R.; Khan, M. S.; Kant, R.; Shahid, S.; Gautam, L.; Hasan, G. M.; Hassan, M. I. Chitin and Its Derivatives: Structural Properties and Biomedical Applications. *Int. J. Biol. Macromol.* **2020** , 164 , 526–539. <https://doi.org/10.1016/j.ijbiomac.2020.07.098>.

(64) Harish Prashanth, K. V.; Tharanathan, R. N. Chitin/Chitosan: Modifications and Their Unlimited Application Potential-an Overview. *Trends Food Sci. Technol.* **2007** , 18 (3), 117–131. <https://doi.org/10.1016/j.tifs.2006.10.022>.

(65) Je, J. Y.; Kim, S. K. *Chitoooligosaccharides as Potential Nutraceuticals. Production and Bioactivities* , 1st ed.; Elsevier Inc., 2012; Vol. 65. <https://doi.org/10.1016/B978-0-12-416003-3.00021-4>.

- (66) Qandil, A. M.; Marji, T. J.; Al-Taani, B. M.; Khaled, A. H.; Badwan, A. A. Depolymerization of HMW into a Predicted LMW Chitosan and Determination of the Degree of Deacetylation to Guarantee Its Quality for Research Use. *J. Excipients Food Chem.* **2018** , *9* (2), 51–63.
- (67) Ma, Z.; Wang, W.; Wu, Y.; He, Y.; Wu, T. Oxidative Degradation of Chitosan to the Low Molecular Water-Soluble Chitosan over Peroxotungstate as Chemical Scissors. *PLoS One* **2014** , *9* (6), 3–9. <https://doi.org/10.1371/journal.pone.0100743>.
- (68) Hsu, S.-C.; Don, T.-M.; Chiu, W.-Y. Free Radical Degradation of Chitosan with Potassium Persulfate. *Polym. Degrad. Stab.* **2002** , *75* (1), 73–83. [https://doi.org/10.1016/S0141-3910\(01\)00205-1](https://doi.org/10.1016/S0141-3910(01)00205-1).
- (69) Yan, J.; Ai, S.; Yang, F.; Zhang, K.; Huang, Y. Study on Mechanism of Chitosan Degradation with Hydrodynamic Cavitation. *Ultrason. Sonochem.* **2020** , *64* (October 2019), 105046. <https://doi.org/10.1016/j.ultsonch.2020.105046>.
- (70) Tsao, C. T.; Chang, C. H.; Lin, Y. Y.; Wu, M. F.; Han, J. L.; Hsieh, K. H. Kinetic Study of Acid Depolymerization of Chitosan and Effects of Low Molecular Weight Chitosan on Erythrocyte Rouleaux Formation. *Carbohydr. Res.* **2011** , *346* (1), 94–102. <https://doi.org/10.1016/j.carres.2010.10.010>.
- (71) Pandit, A.; Indurkar, A.; Deshpande, C.; Jain, R.; Dandekar, P. A Systematic Review of Physical Techniques for Chitosan Degradation. *Carbohydr. Polym. Technol. Appl.* **2021** , *2* (January), 100033. <https://doi.org/10.1016/j.carpta.2021.100033>.
- (72) Lim, L.; Khor, E.; Koo, O. γ Irradiation of Chitosan. *J. Biomed. Mater. Res.* **1998** , *43* (3), 282–290. [https://doi.org/10.1002/\(sici\)1097-4636\(199823\)43:3<282::aid-jbm9>3.3.co;2-x](https://doi.org/10.1002/(sici)1097-4636(199823)43:3<282::aid-jbm9>3.3.co;2-x).
- (73) San Juan, A.; Montembault, A.; Gillet, D.; Say, J. P.; Rouif, S.; Bouet, T.; Royaud, I.; David, L. Degradation of Chitosan-Based Materials after Different Sterilization Treatments. *IOP Conf. Ser. Mater. Sci. Eng.* **2012** , *31* , 2–7. <https://doi.org/10.1088/1757-899X/31/1/012007>.
- (74) Wu, T.; Zivanovic, S.; Hayes, D. G.; Weiss, J. Efficient Reduction of Chitosan Molecular Weight by High-Intensity Ultrasound : Underlying Mechanism. **2008** , No. I, 5112–5119. <https://doi.org/10.1021/jf073136q>.
- (75) Yan, J.; Xu, J.; Ai, S.; Zhang, K.; Yang, F.; Huang, Y. Degradation of Chitosan with Self-Resonating Cavitation. *Arab. J. Chem.* **2020** , *13* (6), 5776–5787. <https://doi.org/10.1016/j.arabjc.2020.04.015>.
- (76) Chen, R. H.; Huang, J. R.; Tsai, M. L.; Tseng, L. Z.; Hsu, C. H. Differences in Degradation Kinetics for Sonolysis, Microfluidization and Shearing Treatments of Chitosan. *Polym. Int.* **2011** , *60* (6), 897–902. <https://doi.org/10.1002/pi.3055>.
- (77) Sørbotten, A.; Horn, S. J.; Eijsink, V. G. H.; Vårum, K. M. Degradation of Chitosans with Chitinase B from *Serratia Marcescens*: Production of Chito-Oligosaccharides and Insight into Enzyme Processivity. *FEBS J.* **2005** , *272* (2), 538–549. <https://doi.org/10.1111/j.1742-4658.2004.04495.x>.
- (78) Nawrotek, K.; Tylman, M.; Adamus-Włodarczyk, A.; Rudnicka, K.; Gatkowska, J.; Wiczorek, M.; Wach, R. Influence of Chitosan Average Molecular Weight on Degradation and Stability of Electrodeposited Conduits. *Carbohydr. Polym.* **2020** , *244* (December 2019), 116484. <https://doi.org/10.1016/j.carbpol.2020.116484>.
- (79) Li, J.; Du, Y. M.; Liang, H. B.; Yao, P. J.; Wei, Y. A. Effect of Immobilized Neutral Protease on the Preparation and Physicochemical Properties of Low Molecular Weight Chitosan and Chito-Oligomers. *J. Appl. Polym. Sci.* **2006** , *102* (5), 4185–4193. <https://doi.org/10.1002/app.24555>.
- (80) Kumar, A. B. V.; Gowda, L. R.; Tharanathan, R. N. Non-Specific Depolymerization of Chitosan by Pronase and Characterization of the Resultant Products. *Eur. J. Biochem.* **2004** , *271* (4), 713–723. <https://doi.org/10.1111/j.1432-1033.2003.03975.x>.
- (81) Shin, S. S.; Lee, Y. C.; Chan, L. The Degradation of Chitosan with the Aid of Lipase from *Rhizopus Japonicus* for the Production of Soluble Chitosan. *J. Food Biochem.* **2001** , *25* (4), 307–321.

<https://doi.org/10.1111/j.1745-4514.2001.tb00742.x>.

- (82) Budnicka, M.; Gadomska-Gajadur, A.; Ruśkowski, P. Wytwarzanie Polimerowych Substytutów Kości. *Tworzywa Sztuczne w Przemysle* **2018** , 43 (1), 56–61.
- (83) Onishi, H.; Machida, Y. Biodegradation and Distribution of Water-Soluble Chitosan in Mice. *Biomaterials* **1999** ,20 (2), 175–182. [https://doi.org/10.1016/S0142-9612\(98\)00159-8](https://doi.org/10.1016/S0142-9612(98)00159-8).
- (84) Szymańska, E.; Winnicka, K. Stability of Chitosan - A Challenge for Pharmaceutical and Biomedical Applications. *Mar. Drugs* **2015** , 13 (4), 1819–1846. <https://doi.org/10.3390/md13041819>.
- (85) Barbosa, J. N.; Amaral, I. F.; Águas, A. P.; Barbosa, M. A. Evaluation of the Effect of the Degree of Acetylation on the Inflammatory Response to 3D Porous Chitosan Scaffolds. *J. Biomed. Mater. Res. - Part A* **2010** , 93 (1), 20–28. <https://doi.org/10.1002/jbm.a.32499>.
- (86) Mi, F. L.; Tan, Y. C.; Liang, H. F.; Sung, H. W. In Vivo Biocompatibility and Degradability of a Novel Injectable-Chitosan-Based Implant. *Biomaterials* **2002** , 23 (1), 181–191. [https://doi.org/10.1016/S0142-9612\(01\)00094-1](https://doi.org/10.1016/S0142-9612(01)00094-1).
- (87) Moura, M. J.; Brochado, J.; Gil, M. H.; Figueiredo, M. M. In Situ Forming Chitosan Hydrogels: Preliminary Evaluation of the in Vivo Inflammatory Response. *Mater. Sci. Eng. C* **2017** ,75 , 279–285. <https://doi.org/10.1016/j.msec.2017.02.050>.
- (88) Qasim, S. B.; Husain, S.; Huang, Y.; Pogorielov, M.; Deineka, V.; Lyndin, M.; Rawlinson, A.; Rehman, I. U. In-Vitro and in-Vivo Degradation Studies of Freeze Gelated Porous Chitosan Composite Scaffolds for Tissue Engineering Applications. *Polym. Degrad. Stab.* **2017** , 136 , 31–38. <https://doi.org/10.1016/j.polymdegradstab.2016.11.018>.
- (89) Halim, A. S.; Keong, L. C.; Zainol, I.; Rashid, A. H. A. Biocompatibility and Biodegradation of Chitosan and Derivatives. *Chitosan-Based Syst. Biopharm. Deliv. Target. Polym. Ther.* **2012** , 57–73. <https://doi.org/10.1002/9781119962977.ch4>.
- (90) Hirano, S.; Noishiki, Y.; Kinugawa, J.; Higashijima, H.; Hayashi, T. Chitin and Chitosan for Use as a Novel Biomedical Material. In *Advances in Biomedical Polymers* ; Gebelein, C. G., Ed.; Springer US: Boston, MA, 1987; pp 285–297. https://doi.org/10.1007/978-1-4613-1829-3_26.
- (91) Hirano, S.; Iwata, M.; Yamanaka, K.; Tanaka, H.; Toda, T.; Inui, H. Enhancement of Serum Lysozyme Activity by Injecting a Mixture of Chitosan Oligosaccharides Intravenously in Rabbits. *Agric. Biol. Chem.* **1991** , 55 (10), 2623–2625. <https://doi.org/10.1080/00021369.1991.10871007>.
- (92) Guo, Z.; Bo, D.; He, Y.; Luo, X.; Li, H. Degradation Properties of Chitosan Microspheres/Poly(L-Lactic Acid) Composite in Vitro and in Vivo. *Carbohydr. Polym.* **2018** , 193 (January), 1–8. <https://doi.org/10.1016/j.carbpol.2018.03.067>.
- (93) Chan, B. P.; Leong, K. W. Scaffolding in Tissue Engineering: General Approaches and Tissue-Specific Considerations. *Eur. Spine J.* **2008** , 17 (SUPPL. 4). <https://doi.org/10.1007/s00586-008-0745-3>.
- (94) Salgado, A. J.; Oliveira, J. M.; Martins, A.; Teixeira, F. G.; Silva, N. A.; Neves, N. M.; Sousa, N.; Reis, R. L. *Tissue Engineering and Regenerative Medicine: Past, Present, and Future* ; 2013; Vol. 108. <https://doi.org/10.1016/B978-0-12-410499-0.00001-0>.
- (95) O'Brien, F. J. Biomaterials & Scaffolds for Tissue Engineering. *Mater. Today* **2011** , 14 (3), 88–95. [https://doi.org/10.1016/S1369-7021\(11\)70058-X](https://doi.org/10.1016/S1369-7021(11)70058-X).
- (96) Middleton, J. C.; Tipton, A. J. Synthetic Biodegradable Polymers as Orthopedic Devices. *Biomaterials* **2000** , 21 (23), 2335–2346. [https://doi.org/10.1016/S0142-9612\(00\)00101-0](https://doi.org/10.1016/S0142-9612(00)00101-0).
- (97) Cruz, D. M. G.; Gomes, M.; Reis, R. L.; Moratal, D.; Salmerón-Sánchez, M.; Ribelles, J. L. G.; Mano, J. F. Differentiation of Mesenchymal Stem Cells in Chitosan Scaffolds with Double Micro and Macroporosity.

- J. Biomed. Mater. Res. - Part A* **2010** ,95 (4), 1182–1193. <https://doi.org/10.1002/jbm.a.32906>.
- (98) Reys, L. L.; Silva, S. S.; Pirraco, R. P.; Marques, A. P.; Mano, J. F.; Silva, T. H.; Reis, R. L. Influence of Freezing Temperature and Deacetylation Degree on the Performance of Freeze-Dried Chitosan Scaffolds towards Cartilage Tissue Engineering. *Eur. Polym. J.* **2017** , 95 (July), 232–240. <https://doi.org/10.1016/j.eurpolymj.2017.08.017>.
- (99) Thein-Han, W. W.; Kitiyanant, Y. Chitosan Scaffolds for in Vitro Buffalo Embryonic Stem-like Cell Culture: An Approach to Tissue Engineering. *J. Biomed. Mater. Res. - Part B Appl. Biomater.* **2007** , 80 (1), 92–101. <https://doi.org/10.1002/jbm.b.30573>.
- (100) Xu, Y.; Xia, D.; Han, J.; Yuan, S.; Lin, H.; Zhao, C. Design and Fabrication of Porous Chitosan Scaffolds with Tunable Structures and Mechanical Properties. *Carbohydr. Polym.* **2017** ,177 (March), 210–216. <https://doi.org/10.1016/j.carbpol.2017.08.069>.
- (101) Abarrategi, A.; Lópiz-Morales, Y.; Ramos, V.; Civantos, A.; López-Duñ, L.; Marco, F.; López-Lacomba, J. L. Chitosan Scaffolds for Osteochondral Tissue Regeneration. *J. Biomed. Mater. Res. - Part A* **2010** , 95 (4), 1132–1141. <https://doi.org/10.1002/jbm.a.32912>.
- (102) Chen, E.; Yang, L.; Ye, C.; Zhang, W.; Ran, J.; Xue, D.; Wang, Z.; Pan, Z.; Hu, Q. An Asymmetric Chitosan Scaffold for Tendon Tissue Engineering: In Vitro and in Vivo Evaluation with Rat Tendon Stem/Progenitor Cells. *Acta Biomater.* **2018** , 73 , 377–387. <https://doi.org/10.1016/j.actbio.2018.04.027>.
- (103) Intini, C.; Elviri, L.; Cabral, J.; Mros, S.; Bergonzi, C.; Bianchera, A.; Flammini, L.; Govoni, P.; Barocelli, E.; Bettini, R.; et al. 3D-Printed Chitosan-Based Scaffolds: An in Vitro Study of Human Skin Cell Growth and an in-Vivo Wound Healing Evaluation in Experimental Diabetes in Rats. *Carbohydr. Polym.* **2018** , 199(April), 593–602. <https://doi.org/10.1016/j.carbpol.2018.07.057>.
- (104) Budnicka, M.; Szymaniak, M.; Gadomska-Gajadur, A. A. Metody Modyfikacji Powierzchni Implantów Polimerowych Do Regeneracji Tkanki Kostnej. **2018** , No. September, 79–96.
- (105) Dash, M.; Samal, S. K.; Douglas, T. E. L.; Schaubroeck, D.; Leeuwenburgh, S. C.; Van Der Voort, P.; Declercq, H. A.; Dubruel, P. Enzymatically Biomineralized Chitosan Scaffolds for Tissue-Engineering Applications. *J. Tissue Eng. Regen. Med.* **2017** , 11(5), 1500–1513. <https://doi.org/10.1002/term.2048>.
- (106) Aday, S.; Gümüşderelioglu, M. Bone-like Apatite-Coated Chitosan Scaffolds: Characterization and Osteoblastic Activity. *Polym. Compos.* **2009** , 16 (2), NA-NA. <https://doi.org/10.1002/pc.20927>.
- (107) Manjubala, I.; Ponomarev, I.; Wilke, I.; Jandt, K. D. Growth of Osteoblast-like Cells on Biomimetic Apatite-Coated Chitosan Scaffolds. *J. Biomed. Mater. Res. - Part B Appl. Biomater.* **2008** ,84 (1), 7–16. <https://doi.org/10.1002/jbm.b.30838>.
- (108) Lu, G.; Zhu, L.; Kong, L.; Zhang, L.; Gong, Y.; Zhao, N.; Zhang, X. Porous Chitosan Microcarriers for Large Scale Cultivation of Cells for Tissue Engineering: Fabrication and Evaluation. *Tsinghua Sci. Technol.* **2006** , 11 (4), 427–432. [https://doi.org/10.1016/S1007-0214\(06\)70212-7](https://doi.org/10.1016/S1007-0214(06)70212-7).
- (109) Ragetly, G. R.; Slavik, G. J.; Cunningham, B. T.; Schaeffer, D. J.; Griffon, D. J. Cartilage Tissue Engineering on Fibrous Chitosan Scaffolds Produced by a Replica Molding Technique. *J. Biomed. Mater. Res. - Part A* **2010** , 93 (1), 46–55. <https://doi.org/10.1002/jbm.a.32514>.
- (110) Di, A.; Sittinger, M.; Risbud, M. V. Chitosan : A Versatile Biopolymer for Orthopaedic Tissue-Engineering. **2005** , 26 , 5983–5990. <https://doi.org/10.1016/j.biomaterials.2005.03.016>.
- (111) Kumari, S.; Tiyyagura, H. R.; Pottathara, Y. B.; Sadasivuni, K. K.; Ponnamm, D.; Douglas, T. E. L.; Skirtach, A. G.; Mohan, M. K. Surface Functionalization of Chitosan as a Coating Material for Orthopaedic Applications: A Comprehensive Review. *Carbohydr. Polym.* **2021** , 255 (November 2020), 117487. <https://doi.org/10.1016/j.carbpol.2020.117487>.

- (112) Gallyamov, M. O.; Chaschin, I. S.; Bulat, M. V.; Bakuleva, N. P.; Badun, G. A.; Chernysheva, M. G.; Kiselyova, O. I.; Khokhlov, A. R. Chitosan Coatings with Enhanced Biostability in Vivo. *J. Biomed. Mater. Res. - Part B Appl. Biomater.* **2018** , *106* (1), 270–277. <https://doi.org/10.1002/jbm.b.33852>.
- (113) Poddar, D.; Jain, P.; Rawat, S.; Mohanty, S. Influence of Varying Concentrations of Chitosan Coating on the Pore Wall of Polycaprolactone Based Porous Scaffolds for Tissue Engineering Application. *Carbohydr. Polym.* **2021** , *259* , 117501. <https://doi.org/10.1016/j.carbpol.2020.117501>.
- (114) Zhu, H.; Ji, A.; Shen, J. Surface Engineering of Poly (DL-Lactic Acid) by Entrapment of Biomacromolecules. *Macromol. Rapid Commun.* **2002** , *23* (14), 819–823. [https://doi.org/10.1002/1521-3927\(20021001\)23:14<819::AID-MARC819>3.0.CO;2-9](https://doi.org/10.1002/1521-3927(20021001)23:14<819::AID-MARC819>3.0.CO;2-9).
- (115) Ma, Z.; Gao, C.; Gong, Y.; Ji, J.; Shen, J. Immobilization of Natural Macromolecules on Poly-L-Lactic Acid Membrane Surface in Order to Improve Its Cytocompatibility. *J. Biomed. Mater. Res.* **2002** , *63* (6), 838–847. <https://doi.org/10.1002/jbm.10470>.
- (116) Chen, S.; Zhao, X.; Du, C. Macroporous Poly (L-Lactic Acid)/Chitosan Nanofibrous Scaffolds through Cloud Point Thermally Induced Phase Separation for Enhanced Bone Regeneration. *Eur. Polym. J.* **2018** , *109* (381), 303–316. <https://doi.org/10.1016/j.eurpolymj.2018.10.003>.
- (117) He, J.; Hu, X.; Cao, J.; Zhang, Y.; Xiao, J.; Peng, li J.; Chen, D.; Xiong, C.; Zhang, L. Chitosan-Coated Hydroxyapatite and Drug-Loaded Polytrimethylene Carbonate/Poly(lactic Acid) Scaffold for Enhancing Bone Regeneration. *Carbohydr. Polym.* **2021** , *253* (September 2020), 117198. <https://doi.org/10.1016/j.carbpol.2020.117198>.
- (118) Al-Nabulsi, A.; Osaili, T.; Sawalha, A.; Olaimat, A. N.; Albiss, B. A.; Mehyar, G.; Ayyash, M.; Holley, R. Antimicrobial Activity of Chitosan Coating Containing ZnO Nanoparticles against E. Coli O157:H7 on the Surface of White Brined Cheese. *Int. J. Food Microbiol.* **2020** , *334* (July), 108838. <https://doi.org/10.1016/j.ijfoodmicro.2020.108838>.
- (119) Lin, M. H.; Wang, Y. H.; Kuo, C. H.; Ou, S. F.; Huang, P. Z.; Song, T. Y.; Chen, Y. C.; Chen, S. T.; Wu, C. H.; Hsueh, Y. H.; et al. Hybrid ZnO/Chitosan Antimicrobial Coatings with Enhanced Mechanical and Bioactive Properties for Titanium Implants. *Carbohydr. Polym.* **2021** , *257* (August 2020), 117639. <https://doi.org/10.1016/j.carbpol.2021.117639>.
- (120) Foss, B. L.; Ghimire, N.; Tang, R.; Sun, Y.; Deng, Y. Bacteria and Osteoblast Adhesion to Chitosan Immobilized Titanium Surface: A Race for the Surface. *Colloids Surfaces B Biointerfaces* **2015** , *134* , 370–376. <https://doi.org/10.1016/j.colsurfb.2015.07.014>.
- (121) Zarghami, V.; Ghorbani, M.; Pooshang, K. Melittin Antimicrobial Peptide Thin Layer on Bone Implant Chitosan-Antibiotic Coatings and Their Bactericidal Properties. *Mater. Chem. Phys.* **2021** , *263* (December 2020), 124432. <https://doi.org/10.1016/j.matchemphys.2021.124432>.
- (122) Wu, D.; Zhu, L.; Li, Y.; Zhang, X.; Xu, S.; Yang, G.; Delair, T. Chitosan-Based Colloidal Polyelectrolyte Complexes for Drug Delivery : A Review. *Carbohydr. Polym.* **2020** , *238* (December 2019). <https://doi.org/10.1016/j.carbpol.2020.116126>.
- (123) Kulkarni, A. D.; Vanjari, Y. H.; Sancheti, K. H.; Patel, H. M.; Belgamwar, V. S.; Surana, S. J.; Pardeshi, C. V. Polyelectrolyte Complexes: Mechanisms, Critical Experimental Aspects, and Applications. *Artif. Cells, Nanomedicine Biotechnol.* **2016** , *44* (7), 1615–1625. <https://doi.org/10.3109/21691401.2015.1129624>.
- (124) Birch, N. P.; Schiffman, J. D. Characterization of Self-Assembled Polyelectrolyte Complex Nanoparticles Formed from Chitosan and Pectin. *Langmuir* **2014** , *30* (12), 3441–3447. <https://doi.org/10.1021/la500491c>.
- (125) de Vasconcelos, C. L.; Bezerril, P. M.; dos Santos, D. E. S.; Dantas, T. N. C.; Pereira, M. R.; Fonseca, J. L. C. Effect of Molecular Weight and Ionic Strength on the Formation of Polyelectrolyte

Complexes Based on Poly(Methacrylic Acid) and Chitosan. *Biomacromolecules* **2006** , 7 (4), 1245–1252. <https://doi.org/10.1021/bm050963w>.

(126) Kaygusuz, H.; Micciulla, S.; Erim, F. B.; von Klitzing, R. Effect of Anionic Surfactant on Alginate-Chitosan Polyelectrolyte Multilayer Thickness. *J. Polym. Sci. Part B Polym. Phys.* **2017** ,55 (23), 1798–1803. <https://doi.org/10.1002/polb.24429>.

(127) Park, H.; Choi, B.; Hu, J.; Lee, M. Injectable Chitosan Hyaluronic Acid Hydrogels for Cartilage Tissue Engineering. *Acta Biomater.* **2013** , 9 (1), 4779–4786. <https://doi.org/10.1016/j.actbio.2012.08.033>.

(128) Hardy, A.; Seguin, C.; Brion, A.; Lavalle, P.; Schaaf, P.; Fournel, S.; Bourel-Bonnet, L.; Frisch, B.; De Giorgi, M. β -Cyclodextrin-Functionalized Chitosan/Alginate Compact Polyelectrolyte Complexes (CoPECs) as Functional Biomaterials with Anti-Inflammatory Properties. *ACS Appl. Mater. Interfaces* **2018** , 10(35), 29347–29356. <https://doi.org/10.1021/acsami.8b09733>.

(129) Li, Z.; Ramay, H. R.; Hauch, K. D.; Xiao, D.; Zhang, M. Chitosan-Alginate Hybrid Scaffolds for Bone Tissue Engineering. *Biomaterials* **2005** , 26 (18), 3919–3928. <https://doi.org/10.1016/j.biomaterials.2004.09.062>.

(130) Wang, C.; Huang, W.; Zhou, Y.; He, L.; He, Z.; Chen, Z.; He, X.; Tian, S.; Liao, J.; Lu, B.; et al. 3D Printing of Bone Tissue Engineering Scaffolds. *Bioact. Mater.* **2020** , 5(1), 82–91. <https://doi.org/10.1016/j.bioactmat.2020.01.004>.

(131) Liao, I. C.; Wan, A. C. A.; Yim, E. K. F.; Leong, K. W. Controlled Release from Fibers of Polyelectrolyte Complexes. *J. Control. Release* **2005** , 104 (2), 347–358. <https://doi.org/10.1016/j.jconrel.2005.02.013>.

(132) Patil, T.; Saha, S.; Biswas, A. Preparation and Characterization of HAp Coated Chitosan-Alginate PEC Porous Scaffold for Bone Tissue Engineering. *Macromol. Symp.* **2017** , 376 (1), 1–9. <https://doi.org/10.1002/masy.201600205>.

(133) Unagolla, J. M.; Alahmadi, T. E.; Jayasuriya, A. C. Chitosan Microparticles Based Polyelectrolyte Complex Scaffolds for Bone Tissue Engineering in Vitro and Effect of Calcium Phosphate. *Carbohydr. Polym.* **2018** , 199 (April), 426–436. <https://doi.org/10.1016/j.carbpol.2018.07.044>.

(134) Hu, Y.; Chen, J.; Fan, T.; Zhang, Y.; Zhao, Y.; Shi, X.; Zhang, Q. Biomimetic Mineralized Hierarchical Hybrid Scaffolds Based on in Situ Synthesis of Nano-Hydroxyapatite/Chitosan/Chondroitin Sulfate/Hyaluronic Acid for Bone Tissue Engineering. *Colloids Surfaces B Biointerfaces* **2017** , 157 , 93–100. <https://doi.org/10.1016/j.colsurfb.2017.05.059>.

(135) Sellgren, K. L.; Ma, T. Perfusion Conditioning of Hydroxyapatite-Chitosan-Gelatin Scaffolds for Bone Tissue Regeneration from Human Mesenchymal Stem Cells. *J. Tissue Eng. Regen. Med.* **2012** , 6 (1), 49–59. <https://doi.org/10.1002/term.396>.

(136) Coimbra, P.; Ferreira, P.; de Sousa, H. C.; Batista, P.; Rodrigues, M. A.; Correia, I. J.; Gil, M. H. Preparation and Chemical and Biological Characterization of a Pectin/Chitosan Polyelectrolyte Complex Scaffold for Possible Bone Tissue Engineering Applications. *Int. J. Biol. Macromol.* **2011** , 48 (1), 112–118. <https://doi.org/10.1016/j.ijbiomac.2010.10.006>.

(137) Li, Q. L.; Chen, Z. Q.; Darvell, B. W.; Liu, L. K.; Jiang, H. B.; Zen, Q.; Peng, Q.; Ou, G. M. Chitosan-Phosphorylated Chitosan Polyelectrolyte Complex Hydrogel as an Osteoblast Carrier. *J. Biomed. Mater. Res. - Part B Appl. Biomater.* **2007** , 82(2), 481–486. <https://doi.org/10.1002/jbm.b.30753>.

(138) Kara, A.; Tamburaci, S.; Tihminlioglu, F.; Havtcioglu, H. Bioactive Fish Scale Incorporated Chitosan Biocomposite Scaffolds for Bone Tissue Engineering. *Int. J. Biol. Macromol.* **2019** ,130 , 266–279. <https://doi.org/10.1016/j.ijbiomac.2019.02.067>.

- (139) Mano, J. F.; Hungerford, G.; Gómez Ribelles, J. L. Bioactive Poly(L-Lactic Acid)-Chitosan Hybrid Scaffolds. *Mater. Sci. Eng. C* **2008** , 28 (8), 1356–1365. <https://doi.org/10.1016/j.msec.2008.03.005>.
- (140) Rajan Unnithan, A.; Ramachandra Kurup Sasikala, A.; Park, C. H.; Kim, C. S. A Unique Scaffold for Bone Tissue Engineering: An Osteogenic Combination of Graphene Oxide–Hyaluronic Acid–Chitosan with Simvastatin. *J. Ind. Eng. Chem.* **2017** , 46 , 182–191. <https://doi.org/10.1016/j.jiec.2016.10.029>.
- (141) Vyas, V.; Kaur, T.; Thirugnanam, A. Chitosan Composite Three Dimensional Macroporous Scaffolds for Bone Tissue Engineering. *Int. J. Biol. Macromol.* **2017** , 104 , 1946–1954. <https://doi.org/10.1016/j.ijbiomac.2017.04.055>.
- (142) Cao, X.; Wang, J.; Liu, M.; Chen, Y.; Cao, Y.; Yu, X. Chitosan-Collagen/Organomontmorillonite Scaffold for Bone Tissue Engineering. *Front. Mater. Sci.* **2015** , 9 (4), 405–412. <https://doi.org/10.1007/s11706-015-0317-5>.
- (143) Jayakumar, R.; Ramachandran, R.; Sudheesh Kumar, P. T.; Divyarani, V. V.; Srinivasan, S.; Chennazhi, K. P.; Tamura, H.; Nair, S. V. Fabrication of Chitin-Chitosan/Nano ZrO₂ Composite Scaffolds for Tissue Engineering Applications. *Int. J. Biol. Macromol.* **2011** , 49 (3), 274–280. <https://doi.org/10.1016/j.ijbiomac.2011.04.020>.
- (144) Dan, Y.; Liu, O.; Liu, Y.; Zhang, Y. Y.; Li, S.; Feng, X. bo; Shao, Z. wu; Yang, C.; Yang, S. H.; Hong, J. bo. Development of Novel Biocomposite Scaffold of Chitosan-Gelatin/Nanohydroxyapatite for Potential Bone Tissue Engineering Applications. *Nanoscale Res. Lett.* **2016** , 11 (1), 1–6. <https://doi.org/10.1186/s11671-016-1669-1>.
- (145) Kavya, K. C.; Jayakumar, R.; Nair, S.; Chennazhi, K. P. Fabrication and Characterization of Chitosan/Gelatin/NSiO₂ Composite Scaffold for Bone Tissue Engineering. *Int. J. Biol. Macromol.* **2013** , 59 , 255–263. <https://doi.org/10.1016/j.ijbiomac.2013.04.023>.
- (146) Beşkardeş, I. G.; Hayden, R. S.; Glettig, D. L.; Kaplan, D. L.; Gümüşderelioğlu, M. Bone Tissue Engineering with Scaffold-Supported Perfusion Co-Cultures of Human Stem Cell-Derived Osteoblasts and Cell Line-Derived Osteoclasts. *Process Biochem.* **2017** , 59 , 303–311. <https://doi.org/10.1016/j.procbio.2016.05.008>.
- (147) Yan, H.; Chen, X.; Feng, M.; Shi, Z.; Zhang, D.; Lin, Q. Layer-by-Layer Assembly of 3D Alginate-Chitosan-Gelatin Composite Scaffold Incorporating Bacterial Cellulose Nanocrystals for Bone Tissue Engineering. *Mater. Lett.* **2017** , 209 , 492–496. <https://doi.org/10.1016/j.matlet.2017.08.093>.
- (148) Thuaksuban, N.; Nuntanaranont, T.; Suttapreyasri, S.; Pattanachot, W.; Sutin, K.; Cheung, L. K. Biomechanical Properties of Novel Biodegradable Poly ϵ -Caprolactone-Chitosan Scaffolds. *J. Investig. Clin. Dent.* **2013** , 4 (1), 26–33. <https://doi.org/10.1111/j.2041-1626.2012.00131.x>.
- (149) Bhowmick, A.; Jana, P.; Pramanik, N.; Mitra, T.; Banerjee, S. L.; Gnanamani, A.; Das, M.; Kundu, P. P. Multifunctional Zirconium Oxide Doped Chitosan Based Hybrid Nanocomposites as Bone Tissue Engineering Materials. *Carbohydr. Polym.* **2016** , 151 , 879–888. <https://doi.org/10.1016/j.carbpol.2016.06.034>.
- (150) Januariyasa, I. K.; Ana, I. D.; Yusuf, Y. Nanofibrous Poly(Vinyl Alcohol)/Chitosan Contained Carbonated Hydroxyapatite Nanoparticles Scaffold for Bone Tissue Engineering. *Mater. Sci. Eng. C* **2020** , 107 , 110347. <https://doi.org/10.1016/j.msec.2019.110347>.
- (151) Shakir, M.; Jolly, R.; Khan, M. S.; Rauf, A.; Kazmi, S. Nano-Hydroxyapatite/ β -CD/Chitosan Nanocomposite for Potential Applications in Bone Tissue Engineering. *Int. J. Biol. Macromol.* **2016** , 93 , 276–289. <https://doi.org/10.1016/j.ijbiomac.2016.08.046>.
- (152) Li, X.; Xu, P.; Cheng, Y.; Zhang, W.; Zheng, B.; Wang, Q. Nano-Pearl Powder/Chitosan-Hyaluronic Acid Porous Composite Scaffold and Preliminary Study of Its Osteogenesis Mechanism. *Mater. Sci. Eng. C* **2020** , 111 (January). <https://doi.org/10.1016/j.msec.2020.110749>.

- (153) Saravani, S.; Ebrahimian-Hosseiniabadi, M.; Mohebbi-Kalhari, D. Polyglycerol Sebacate/Chitosan/Gelatin Nano-Composite Scaffolds for Engineering Neural Construct. *Mater. Chem. Phys.* **2019**, *222*, 147–151. <https://doi.org/10.1016/j.matchemphys.2018.10.010>.
- (154) Akmammedov, R.; Huysal, M.; Isik, S.; Senel, M. Preparation and Characterization of Novel Chitosan/Zelite Scaffolds for Bone Tissue Engineering Applications. *Int. J. Polym. Mater. Polym. Biomater.* **2018**, *67* (2), 110–118. <https://doi.org/10.1080/00914037.2017.1309539>.
- (155) Maji, K.; Dasgupta, S.; Pramanik, K.; Bissoyi, A. Preparation and Evaluation of Gelatin-Chitosan-Nanobioglass 3D Porous Scaffold for Bone Tissue Engineering. *Int. J. Biomater.* **2016**, *2016*. <https://doi.org/10.1155/2016/9825659>.
- (156) Khan, S.; Garg, M.; Chockalingam, S.; Gopinath, P.; Kundu, P. P. *TiO₂ Doped Chitosan/Poly (Vinyl Alcohol) Nanocomposite Film with Enhanced Mechanical Properties for Application in Bone Tissue Regeneration*; Elsevier B.V, 2020; Vol. 143. <https://doi.org/10.1016/j.ijbiomac.2019.11.246>.
- (157) Bosco, R.; Van Den Beucken, J. V.; Leeuwenburgh, S.; Jansen, J. Surface Engineering for Bone Implants: A Trend from Passive to Active Surfaces. *Coatings* **2012**, *2* (3), 95–119. <https://doi.org/10.3390/coatings2030095>.
- (158) Paital, S. R.; Dahotre, N. B. Calcium Phosphate Coatings for Bio-Implant Applications: Materials, Performance Factors, and Methodologies. *Mater. Sci. Eng. R Reports* **2009**, *66* (1–3), 1–70. <https://doi.org/10.1016/j.mser.2009.05.001>.
- (159) Anselme, K. Osteoblast Adhesion on Biomaterials. *Biomaterials* **2000**, *21* (7), 667–681. [https://doi.org/10.1016/S0142-9612\(99\)00242-2](https://doi.org/10.1016/S0142-9612(99)00242-2).
- (160) Gadomska-Gajadur, A.; Lojek, K.; Szymaniak, M.; Gadomska, A. Materiały Porowate Do Regeneracji Tkanki Chrzestnej i Kostnej. *Wyr. Med.* **2018**, No. August, 51–58.
- (161) Cao, S.; Zhao, Y.; Hu, Y.; Zou, L.; Chen, J. New Perspectives: In-Situ Tissue Engineering for Bone Repair Scaffold. *Compos. Part B Eng.* **2020**, *202* (September), 108445. <https://doi.org/10.1016/j.compositesb.2020.108445>.
- (162) Habibovic, P.; de Groot, K. Osteoinductive Biomaterials—Properties and Relevance in Bone Repair. *J. Tissue Eng. Regen. Med.* **2007**, *1* (1), 25–32. <https://doi.org/10.1002/term.5>.
- (163) Nowacka, M. Biomateriały Stosowane W Inżynierii Komórkowej I Medycynie Regeneracyjnej Biomaterials for Tissue Engineering and Regenerative Medicine. *Wiadomości Chem.* **2012**, *66*, 9–10.
- (164) Cavalcanti-Adam, E. A.; Aydin, D.; Hirschfeld-Warneken, V. C.; Spatz, J. P. Cell Adhesion and Response to Synthetic Nanopatterned Environments by Steering Receptor Clustering and Spatial Location. *HFSP J.* **2008**, *2* (5), 276–285. <https://doi.org/10.2976/1.2976662>.
- (165) Roach, P.; Eglin, D.; Rohde, K.; Perry, C. C. Modern Biomaterials: A Review - Bulk Properties and Implications of Surface Modifications. *J. Mater. Sci. Mater. Med.* **2007**, *18* (7), 1263–1277. <https://doi.org/10.1007/s10856-006-0064-3>.
- (166) Xiao, D.; Guo, T.; Yang, F.; Feng, G.; Shi, F.; Li, J.; Wang, D.; Duan, K.; Weng, J. In Situ Formation of Nanostructured Calcium Phosphate Coatings on Porous Hydroxyapatite Scaffolds Using a Hydrothermal Method and the Effect on Mesenchymal Stem Cell Behavior. Your Article Is Registered as a Regular Item and Is Being Processed for Inclusion. *Ceram. Int.* **2017**, *43* (1), 1588–1596. <https://doi.org/10.1016/j.ceramint.2016.10.023>.
- (167) Tian, Y.; Liu, H.; Sheldon, B. W.; Webster, T. J.; Yang, S.; Yang, H.; Yang, L. Surface Energy-Mediated Fibronectin Adsorption and Osteoblast Responses on Nanostructured Diamond. *J. Mater. Sci. Technol.* **2019**, *35* (5), 817–823. <https://doi.org/10.1016/j.jmst.2018.11.009>.

- (168) Comelles, J.; Estévez, M.; Martínez, E.; Samitier, J. The Role of Surface Energy of Technical Polymers in Serum Protein Adsorption and MG-63 Cells Adhesion. *Nanomedicine Nanotechnology, Biol. Med.* **2010** , 6 (1), 44–51. <https://doi.org/10.1016/j.nano.2009.05.006>.
- (169) Yang, L.; Li, Y.; Sheldon, B. W.; Webster, T. J. Altering Surface Energy of Nanocrystalline Diamond to Control Osteoblast Responses. *J. Mater. Chem.* **2012** , 22 (1), 205–214. <https://doi.org/10.1039/c1jm13593g>.
- (170) Keselowsky, B. G.; Collard, D. M.; García, A. J. Integrin Binding Specificity Regulates Biomaterial Surface Chemistry Effects on Cell Differentiation. *Proc. Natl. Acad. Sci. U. S. A.* **2005** ,102 (17), 5953–5957. <https://doi.org/10.1073/pnas.0407356102>.
- (171) Curran, J. M.; Chen, R.; Hunt, J. A. Controlling the Phenotype and Function of Mesenchymal Stem Cells in Vitro by Adhesion to Silane-Modified Clean Glass Surfaces. *Biomaterials* **2005** ,26 (34), 7057–7067. <https://doi.org/10.1016/j.biomaterials.2005.05.008>.
- (172) Curran, J. M.; Chen, R.; Hunt, J. A. The Guidance of Human Mesenchymal Stem Cell Differentiation in Vitro by Controlled Modifications to the Cell Substrate. *Biomaterials* **2006** ,27 (27), 4783–4793. <https://doi.org/10.1016/j.biomaterials.2006.05.001>.
- (173) Sandra, S.; Brygida, Z.; Lagan, S. Porównanie Związalności Oraz Swobodnej Energii Powierzchniowej Biomateriałów i Tkanki Kostnej. *Aktualne Problemy Biomechaniki* . 2013.
- (174) Govindasamy, K.; Dahlan, N. A.; Janarthanan, P.; Goh, K. L.; Chai, S. P.; Pasbakhsh, P. Electrospun Chitosan/Polyethylene-Oxide (PEO)/Hyalosites (HAL) Membranes for Bone Regeneration Applications. *Appl. Clay Sci.* **2020** , 190 (March), 105601. <https://doi.org/10.1016/j.clay.2020.105601>.
- (175) Sukul, M.; Sahariah, P.; Lauzon, H. L.; Borges, J.; Másson, M.; Mano, J. F.; Haugen, H. J.; Reseland, J. E. In Vitro Biological Response of Human Osteoblasts in 3D Chitosan Sponges with Controlled Degree of Deacetylation and Molecular Weight. *Carbohydr. Polym.* **2021** , 254 (November 2020). <https://doi.org/10.1016/j.carbpol.2020.117434>.
- (176) Florencio-Silva, R.; Sasso, G. R. da S.; Sasso-Cerri, E.; Simões, M. J.; Cerri, P. S. Biology of Bone Tissue: Structure, Function, and Factors That Influence Bone Cells. *Biomed Res. Int.* **2015** , 2015 (6), 1–17. <https://doi.org/10.1155/2015/421746>.
- (177) Ducy, P.; Schinke, T.; Karsenty, G. The Osteoblast: A Sophisticated Fibroblast under Central Surveillance. *Science (80-)*. **2000** , 289 (5484), 1501–1504. <https://doi.org/10.1126/science.289.5484.1501>.
- (178) Dirckx, N.; Moorer, M. C.; Clemens, T. L.; Riddle, R. C. The Role of Osteoblasts in Energy Homeostasis. *Nat. Rev. Endocrinol.* **2019** , 15 (11), 651–665. <https://doi.org/10.1038/s41574-019-0246-y>.
- (179) Datta, H. K.; Ng, W. F.; Walker, J. A.; Tuck, S. P.; Varanasi, S. S. The Cell Biology of Bone Metabolism. *J. Clin. Pathol.* **2008** , 61 (5), 577–587. <https://doi.org/10.1136/jcp.2007.048868>.
- (180) Aarden, E. M.; Burger, E. H.; Nijweide, P. J. Function of Osteocytes in Bone. [Review] [75 Refs]. *J. Cell. Biochem.* **1994** , 55 (3), 287–299.
- (181) Bonewald, L. F. Cell–Cell and Cell–Matrix Interactions in Bone. In *Handbook of Cell Signaling* ; Elsevier, 2010; Vol. 1, pp 2647–2662. <https://doi.org/10.1016/B978-0-12-374145-5.00313-2>.
- (182) Klein-Nulend, J.; Bonewald, L. F. *The Osteocyte* ; Elsevier Inc., 2019. <https://doi.org/10.1016/B978-0-12-814841-9.00006-3>.
- (183) Brown, J. L.; Kumbar, S. G.; Laurencin, C. T. *Bone Tissue Engineering* , Third Edit.; Elsevier, 2013. <https://doi.org/10.1016/B978-0-08-087780-8.00113-3>.
- (184) Kakol, P. T. *Biologia Kompendium* , 1st ed.; Świat Książki: Warszawa, 2007.
- (185) Kalfas, I. H. Principles of Bone Healing. *Neurosurgical focus* . 2001, pp 10–13. <https://doi.org/10.3171/foc.2001.10.4.2>.

- (186) Morgan, E. F.; Barnes, G. L.; Einhorn, T. A. *The Bone Organ System. Form and Function* , Fourth Edi.; Elsevier, 2013. <https://doi.org/10.1016/B978-0-12-415853-5.00001-7>.
- (187) Jang, J. H.; Castano, O.; Kim, H. W. Electrospun Materials as Potential Platforms for Bone Tissue Engineering. *Adv. Drug Deliv. Rev.* **2009** , *61* (12), 1065–1083. <https://doi.org/10.1016/j.addr.2009.07.008>.
- (188) Yang, J.; Ueharu, H.; Mishina, Y. Energy Metabolism: A Newly Emerging Target of BMP Signaling in Bone Homeostasis. *Bone***2020** , *138* (June), 115467. <https://doi.org/10.1016/j.bone.2020.115467>.
- (189) Lin, X.; Patil, S.; Gao, Y. G.; Qian, A. The Bone Extracellular Matrix in Bone Formation and Regeneration. *Front. Pharmacol.***2020** , *11* (May), 1–15. <https://doi.org/10.3389/fphar.2020.00757>.
- (190) Johansen, J. S.; Williamson, M. K.; Rice, J. S.; Price, P. A. Identification of Proteins Secreted by Human Osteoblastic Cells in Culture. *J. Bone Miner. Res.* **1992** , *7* (5), 501–512. <https://doi.org/10.1002/jbmr.5650070506>.
- (191) Gentili, C.; Cancedda, R. Cartilage and Bone Extracellular Matrix. *Curr. Pharm. Des.* **2009** , *15* (12), 1334–1348. <https://doi.org/10.2174/138161209787846739>.
- (192) Hua, R.; Ni, Q.; Eliason, T. D.; Han, Y.; Gu, S.; Nicolella, D. P.; Wang, X.; Jiang, J. X. Biglycan and Chondroitin Sulfate Play Pivotal Roles in Bone Toughness via Retaining Bound Water in Bone Mineral Matrix. *Matrix Biol.* **2020** , *94* , 95–109. <https://doi.org/10.1016/j.matbio.2020.09.002>.
- (193) Li, X.; Pennisi, A.; Yaccoby, S. Role of Decorin in the Antimyeloma Effects of Osteoblasts. *Blood* **2008** , *112* (1), 159–168. <https://doi.org/10.1182/blood-2007-11-124164>.
- (194) Hosseini, S.; Naderi-Manesh, H.; Vali, H.; Baghaban Eslaminejad, M.; Azam Sayahpour, F.; Sheibani, S.; Faghihi, S. Contribution of Osteocalcin-Mimetic Peptide Enhances Osteogenic Activity and Extracellular Matrix Mineralization of Human Osteoblast-like Cells. *Colloids Surfaces B Biointerfaces* **2019** , *173* (October 2018), 662–671. <https://doi.org/10.1016/j.colsurfb.2018.10.035>.
- (195) Siggelkow, H.; Schmidt, E.; Hennies, B.; Hüfner, M. Evidence of Downregulation of Matrix Extracellular Phosphoglycoprotein during Terminal Differentiation in Human Osteoblasts. *Bone***2004** , *35* (2), 570–576. <https://doi.org/10.1016/j.bone.2004.03.033>.
- (196) Singh, A.; Gill, G.; Kaur, H.; Amhmed, M.; Jakhu, H. Role of Osteopontin in Bone Remodeling and Orthodontic Tooth Movement: A Review. *Prog. Orthod.* **2018** , *19* (1). <https://doi.org/10.1186/s40510-018-0216-2>.
- (197) Saito, K.; Nakatomi, M.; Ohshima, H. Dentin Matrix Protein 1 Compensates for Lack of Osteopontin in Regulating Odontoblastlike Cell Differentiation after Tooth Injury in Mice. *J. Endod.***2020** , *46* (1), 89–96. <https://doi.org/10.1016/j.joen.2019.10.002>.
- (198) Bellahcène, A.; Castronovo, V.; Ogbureke, K. U. E.; Fisher, L. W.; Fedarko, N. S. Small Integrin-Binding Ligand N-Linked Glycoproteins (SIBLINGs): Multifunctional Proteins in Cancer. *Nat. Rev. Cancer***2008** , *8* (3), 212–226. <https://doi.org/10.1038/nrc2345>.
- (199) Teitelbaum, S. L. Bone Resorption by Osteoclasts. *Science (80-.)*. **2000** , *289* (5484), 1504–1508. <https://doi.org/10.1126/science.289.5484.1504>.
- (200) Bossard, M. J.; Tomaszek, T. A.; Thompson, S. K.; Amegadzie, B. Y.; Hanning, C. R.; Jones, C.; Kurdyla, J. T.; McNulty, D. E.; Drake, F. H.; Gowen, M.; et al. Proteolytic Activity of Human Osteoclast Cathepsin K: Expression, Purification, Activation, and Substrate Identification. *J. Biol. Chem.* **1996** , *271* (21), 12517–12524. <https://doi.org/10.1074/jbc.271.21.12517>.
- (201) Dhiman, H. K.; Ray, A. R.; Panda, A. K. Three-Dimensional Chitosan Scaffold-Based MCF-7 Cell Culture for the Determination of the Cytotoxicity of Tamoxifen. *Biomaterials* **2005** , *26* (9), 979–986. <https://doi.org/10.1016/j.biomaterials.2004.04.012>.

(202) Amir, L. R.; Suniarti, D. F.; Utami, S.; Abbas, B. Chitosan as a Potential Osteogenic Factor Compared with Dexamethasone in Cultured Macaque Dental Pulp Stromal Cells. *Cell Tissue Res.***2014** , 358 (2), 407–415. <https://doi.org/10.1007/s00441-014-1938-1>.

Figure LegendsFigure 1. Chitin (a) and chitosan (b). Figure 2. Production of chitosan. Figure 3. Cell adhesion to biomaterial. After biomaterial implementation thin water layer is formed on the surface, followed by protein adhesion. Cells recognise proteins and adhere to the biomaterial, allowing the tissue to regenerate.**Table Legends**Table 1. Chitosan solubility. Table 2. Examples of polyelectrolyte complexes with chitosan in tissue engineering Table 3. Examples of chitosan composites in bone tissue engineering




Figure 1. Chitin (a) and chitosan (b).




Figure 2. Production of chitosan.




Figure 3. Cell adhesion to biomaterial. After biomaterial implementation thin water layer is formed on the surface, followed by protein adhesion. Cells recognise proteins and adhere to the biomaterial, allowing the tissue to regenerate.

Table 1. Chitosan solubility.³⁰

Solvent	Solubility
Deionised water	-
2% aqueous acetic acid solution	soluble
Methanol	-
Ethanol	-

Solvent	Solubility
Isopropanol	-
Toluene	-
<i>N</i> -Methyl-2-Pyrrolidone (NMP)	-
Methyl ethyl ketone (MEK)	-
Tetrahydrofuran (THF)	-
Dimethyl formamide (DMF)	-
Dimethyl sulfoxide (DMSO)	-

Table 2. Examples of polyelectrolyte complexes with chitosan in tissue engineering

Polycation	Polyanion	Abbreviation	Type	Reference
Chitosan	Alginate	CS/Alg	scaffolds	128–132
Chitosan	Carboxymethylcellulose	CS/CMC	scaffolds	133
Chitosan	Chondroitin sulfate / hyaluronic acid / nano-hydroxyapatite	CS/CSA/HA/nHAP	scaffolds	134
Chitosan	Gelatin / hydroxyapatite	CS/Ge/HAP	scaffolds	135
Chitosan	Hyaluronic Acid	CS/HA	nanoparticles	47
Chitosan	Pectin	CS/Pc	scaffolds	49,136
Chitosan	Phosphorylated chitosan	CS/PCS	sponges	137

Table 3. Examples of chitosan composites in bone tissue engineering

Composite compounds	Abbreviation	Type	Source
Chitosan + hyaluronic acid	CS+HA	Porous hydrogel	146
Alginate + bacterial cellulose nanocrystals + chitosan + gelatin	Alg+BCNs+CS+GT	Porous scaffolds	147
Polycaprolactone + chitosan	PCL+CS	Monolayer scaffolds	148
Chitosan + organomontmorillonite + hydroxyapatite + ZrO ₂	CS+OMMT+HAP+ZrO ₂	Films	149
poly(vinyl alcohol) + chitosan + carbonated hydroxyapatite	PVA+CS+CHAP	Nanofibrous scaffolds	150
β-cyclodextrin + nano-hydroxyapatite + chitosan	nHAP+β-CD+CS	Nanoparticles	151
Chitosan + hyaluronic acid + nano-pearl powder	CS/HA+nPP	Porous scaffolds	152
Polyglycerol sebacate + chitosan + gelatin	PGS+CS+Ge	Nanofibrous scaffolds	153
Zeolite A + chitosan	-	Porous scaffolds	154
Gelatin + chitosan + nanobioglass	Ge+CS+nBG	Porous scaffolds	155

Composite compounds	Abbreviation	Type	Source
Chitosan+poly(vinyl alcohol)+TiO ₂	CS+PVA+TiO ₂	Films	156

